

1 **Sterile faecal filtrate transplantation alters phage-microbe dynamics in**  
2 **individuals with metabolic syndrome: a double blind, randomised, placebo-**  
3 **controlled clinical trial assessing efficacy and safety**

4  
5 Koen Wortelboer<sup>1,2,3,7</sup>, Patrick A. de Jonge<sup>1,2,3,7</sup>, Torsten P.M. Scheithauer<sup>1,2,3</sup>, Ilias  
6 Attaye<sup>2,3,4</sup>, E. Marleen Kemper<sup>1,5</sup>, Max Nieuwdorp<sup>1,2,3,4,6</sup>, Hilde Herrema<sup>1,2,3,\*</sup>

7  
8 <sup>1</sup>: Amsterdam UMC location University of Amsterdam, Experimental Vascular Medicine,  
9 Amsterdam, The Netherlands.

10 <sup>2</sup>: Amsterdam Cardiovascular Sciences, Diabetes & Metabolism, Amsterdam, The  
11 Netherlands.

12 <sup>3</sup>: Amsterdam Gastroenterology Endocrinology Metabolism, Endocrinology, metabolism and  
13 nutrition, Amsterdam, The Netherlands.

14 <sup>4</sup>: Amsterdam UMC location University of Amsterdam, Vascular Medicine, Amsterdam, The  
15 Netherlands.

16 <sup>5</sup>: Amsterdam UMC location University of Amsterdam, Department of Pharmacy and Clinical  
17 Pharmacology, Amsterdam, The Netherlands.

18 <sup>6</sup>: Amsterdam UMC location Vrije University Medical Center, Department of Internal  
19 Medicine, Diabetes Center, Amsterdam, The Netherlands.

20 <sup>7</sup>: These authors contributed equally.

21 \*: Correspondence: Meibergreef 9, 1105AZ Amsterdam; [h.j.herrema@amsterdamumc.nl](mailto:h.j.herrema@amsterdamumc.nl)

22

23 **Keywords**

24 bacteriophages; gastrointestinal microbiome; faecal microbiota transplantation; sterile faecal  
25 filtrate transplantation; metabolic syndrome; faecal virome transplantation

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **ABSTRACT**

27 **Objective**

28 Bacteriophages (phages) are viruses of bacteria and have been shown to shape microbial  
29 communities. Previous studies have shown that altering the microbiota through faecal  
30 microbiota transplantation (FMT) can improve insulin resistance in individuals with metabolic  
31 syndrome (MetSyn). Interestingly, similar effects were observed in diet-induced obese mice  
32 after a faecal virome transplantation (FVT), raising the question whether phages of a healthy  
33 donor can improve glucose metabolism in individuals with MetSyn as well.

34 **Design**

35 We performed a double-blind, randomised, placebo-controlled pilot study in which 24  
36 individuals with MetSyn were randomised to receive a sterile faecal filtrate transplantation  
37 (FFT) from a lean healthy donor or a placebo. From baseline up to 28 days, we assessed  
38 safety, effects on glucose metabolism, and longitudinal changes within the bacteriome and  
39 phageome.

40 **Results**

41 The FFT was well-tolerated and safe and glucose variability (time between 3.9-10 mmol/L  
42 glucose) improved in the week following the FFT. Glucose excursions during oral glucose  
43 tolerance tests were comparable in both the FFT and placebo group after 28 days. The phage  
44 virion composition was significantly altered two days after FFT as compared to placebo.  
45 Moreover, we found that FFT induced more virulent phage-microbe interactions within the first  
46 two days after administration, while these interactions appeared more temperate in the  
47 placebo group.

48 **Conclusion**

49 We provide evidence that gut phages from a healthy donor can be safely administered to  
50 transiently alter the gut microbiota of recipients, thereby providing a critical basis for follow-up  
51 studies.

52 **Trial registration number**

53 Dutch Trial Registry: NL8289

54

## 55 INTRODUCTION

56 The metabolic syndrome (MetSyn) constitutes a major global health concern<sup>1</sup>. This  
57 combination of clinical manifestations that are associated with insulin resistance affects nearly  
58 a quarter of the world population and increases the risk for cardiometabolic disease, such as  
59 type 2 diabetes (T2D) and cardiovascular disease<sup>2,3</sup>. The intestinal microbiota are increasingly  
60 seen as contributors to these diseases, e.g., through production of certain microbial  
61 metabolites and induction of low-grade inflammation<sup>4,5</sup>.

62  
63 Previously reported microbial effects on human health have been mainly attributed to the  
64 bacterial component of the microbiota<sup>6</sup>. However, the gut microbiome is an ecosystem, which,  
65 in addition to bacteria, contains viruses, archaea, fungi, and protists<sup>7</sup>. The viral component  
66 predominantly comprises bacteriophages (98%)<sup>8</sup>, which are present in similar numbers as  
67 bacteria in the gut<sup>9</sup>. Bacteriophages (phages from hereon) are bacterial viruses that  
68 exclusively infect bacteria and, by doing so, often either kill bacteria (lysis) or incorporate  
69 themselves into the bacterial genome (lysogeny)<sup>10</sup>. Consequently, phages shape microbial  
70 communities in many ecosystems<sup>11,12</sup>. Moreover, phages have been implicated in human  
71 (gastrointestinal) disease<sup>13–16</sup>, including diabetes<sup>17,18</sup>. We recently described decreased  
72 richness and diversity of the gut phageome in MetSyn, together with a larger inter-individual  
73 variation and altered composition<sup>19</sup>.

74  
75 Considering their ability to modulate gut bacteria and their function<sup>20</sup>, phages are of special  
76 interest in ongoing endeavours to alter the human gut microbiome to benefit human health.  
77 Furthermore, the emergence of multidrug-resistant bacteria has led to an increasing interest  
78 in phage therapy, in which host-specific phages target specific pathogenic bacteria without  
79 affecting the commensal microbiota<sup>21,22</sup>. Such phage cocktails can be very effective in treating  
80 monoclonal bacterial infections, but are in general not sufficient to (beneficially) alter a  
81 complete microbiome<sup>23,24</sup>. Therefore, there is growing interest in the transfer of virus-like  
82 particles (VLP) isolated from the faecal microbiota, generally called a faecal virome  
83 transplantation (FVT). In mice, it has been shown that FVT induced a comparable effect as a  
84 faecal microbiota transplantation (FMT), in which the complete faecal microbiota of a healthy  
85 donor is transferred<sup>25,26</sup>. Moreover, in a small human pilot study, an FMT depleted of bacteria,  
86 also known as a sterile faecal filtrate transplantation (FFT), was successful in curing five  
87 individuals from a recurrent *Clostridioides difficile* infection<sup>27</sup>. Compared to FMTs, an FFT or  
88 FVT depleted of living microorganisms has a lower risk of transferring unknown pathogenic  
89 bacteria, which might improve safety.

90

91 Modulation of gut microbiota composition through FMT has been shown to improve peripheral  
92 insulin sensitivity in individuals with MetSyn<sup>28,29</sup>. Moreover, an FVT from lean donor mice was  
93 able to decrease weight gain and normalize blood glucose tolerance in diet-induced obese  
94 mice<sup>30</sup>. This effect was likely mediated through alterations in the gut microbiota induced by  
95 phages, as prior treatment with antibiotics disrupted the bacterial hosts and thereby  
96 counteracted the effect of the FVT. This raised the question whether transfer of faecal phages  
97 could induce a similar effect as FMT in human individuals with MetSyn.

98

99 In this double-blind, randomized, placebo-controlled pilot study, we provide proof of concept  
100 that gut phages from lean healthy donors can be safely administered to MetSyn recipients.  
101 Moreover, these phages have the potential to improve glycemic variability and alter phage-  
102 microbe dynamics. Although follow up studies in well-matched donor-recipient pairs are  
103 needed, this study provides a critical basis to do so.

104

## 105 **RESULTS**

### 106 **Inclusion of subjects and donors**

107 A total of 82 subjects signed the informed consent form and were screened from October  
108 2019, of which 24 subjects were included and finished the study before December 2020 (figure  
109 S1A). Most subjects were excluded because they did not have MetSyn according to the  
110 National Cholesterol Education Program (NCEP) criteria for the metabolic syndrome<sup>31</sup>. For the  
111 faeces donors, 24 subjects signed informed consent and were stepwise screened, resulting  
112 in 6 eligible donors (figure S1B). Potential donors failed screening mainly due to carriage of  
113 parasites (11/24, 46%), followed by positive stool tests for pathogens (4/24, 17%) and  
114 exclusion based on questionnaire (3/24, 13%). Of these 6 eligible donors, only 3 (3/24, 13%)  
115 donated faeces for the production of a sterile faecal filtrate. Therefore, an additional 2 donors  
116 who were already actively donating for other FMT studies were included<sup>32</sup>.

117

118 The 24 included MetSyn subjects were randomly assigned to receive an FFT (n=12) or  
119 placebo (n=12). As shown in table 1, both groups were similar in baseline characteristics, such  
120 as age, sex, body mass index (BMI), and other MetSyn-associated parameters. Only the  
121 systolic blood pressure was significantly higher in the placebo group, although this difference  
122 disappeared at baseline and follow-up visits and was therefore probably a case of white coat  
123 hypertension during the screening. None of the individuals with MetSyn used concomitant  
124 medication and their diets were similar (table S1). Compared to the healthy donors, the  
125 MetSyn subjects differed, as expected, in almost every aspect of MetSyn-associated  
126 parameters (table 1).

127

128 **FFT is safe and well-tolerated**

129 The FFT was well-tolerated by the participants and there were no serious adverse events.  
130 Compared to the placebo group, subjects in the FFT group did report more adverse events  
131 (AEs) that were likely or possibly related to the intervention (eight vs two AEs), although this  
132 difference was not statistically significant (table 2). All adverse events that may have been  
133 related to the intervention were mild gastrointestinal complaints, such as diarrhoea,  
134 constipation, bloating, and nausea. Looking at the clinical safety parameters for liver and renal  
135 function, haematology, and inflammation, we did not observe any differences between the  
136 FFT and placebo groups (table 2). Interestingly, in both groups there was a significant increase  
137 in urea levels, which could be explained by the laxative that was used the evening prior to day  
138 0, leading to less degradation of amino acids through the liver at baseline, and therefore less  
139 urea.

140

141 **FFT improved glucose variability**

142 Prior to the intervention and after 28 days at follow-up, subjects underwent an oral glucose  
143 tolerance test (OGTT) to assess their glucose metabolism (figure 1A). Glucose and C-peptide  
144 excursions during the OGTT at day 28 after the intervention were similar in the FFT and  
145 placebo group (figure 1B-D), as were within group alterations (day 0 vs day 28). In addition,  
146 we observed similar fasting glucose and insulin levels, insulin resistance (HOMA-IR) (figure  
147 1E), and HbA1c values between the FFT and placebo group at day 28 (table 3). Interestingly,  
148 we did observe a significant increase in fasted insulin levels and associated HOMA-IR values  
149 between day 0 and 28 within both the FFT and placebo group. However, when comparing  
150 these two measures between the screening visit and day 28, they were similar. We can only  
151 speculate that this drop in insulin levels and associated HOMA-IR value at the baseline visit  
152 resulted from the laxative use the day prior to the intervention. Other baseline characteristics  
153 remained stable after intervention and were similar between the FFT and placebo group, such  
154 as BMI, blood pressure and cholesterol (table 3).

155

156 In addition to the OGTT, subjects wore a continuous glucose monitoring (CGM) device  
157 (Freestyle Libre) from one week prior till one week after intervention. Looking at the results  
158 from the CGM measurements, the FFT and placebo group showed overall similar glucose  
159 levels and glucose variability markers after intervention (table S2). However, within the FFT  
160 group we identified a nominal significant improvement in the time between 3.9-10 mmol/L  
161 glucose after intervention (from 95.5% to 97.5%, p-value = 0.02)(figure 1F). This indicated an  
162 improvement in glucose variability within the FFT group in the week after intervention.

163

164

## 165 **Bacterial and viral diversity remain stable after FFT**

166 To assess the effect of the FFT on the bacteriome and phageome, we collected multiple faecal  
167 samples from baseline up to day 28, and performed whole genome shotgun (WGS)  
168 sequencing (figure 2A)<sup>33</sup>. The phage populations derived from this WGS fraction mainly  
169 consist of integrated prophages. To study phage virions, VLPs were isolated from the same  
170 faecal samples, lysed, and the purified DNA was shotgun sequenced as previously  
171 described<sup>19</sup>. After combining all viral sequences from WGS and VLP fractions, we clustered  
172 them at 95% similarity into viral populations (VPs), a level comparable to species in bacteria<sup>34</sup>.

173  
174 Analysis of beta diversity showed that both the VLP and WGS phageomes were  
175 indistinguishable between donor and MetSyn participants at baseline (VLP (figure S2A),  
176 PERMANOVA  $p = 0.725$ ; WGS (figure S2B), PERMANOVA  $p = 0.672$ ). While this defies our  
177 earlier findings<sup>19</sup>, this is likely due to the highly individual-specific viromes and the relatively  
178 small size of our study. Notably, the VLP phageome was radically different from the WGS  
179 phageome (figure S2C, PERMANOVA  $p = 0.001$ ). This is one of the first studies to directly  
180 compare the VLP and WGS phageomes within the same patient longitudinally, as previous  
181 studies used different cohorts to compare the VLP and WGS phageomes<sup>9</sup>.

182  
183 Next, we looked at the effect of FFT on the bacterial and viral richness (figure 2B) and alpha  
184 diversity in MetSyn subjects (figure 2C). These were comparable throughout the study  
185 between the FFT and placebo intervention. Interestingly, in both groups the bacterial richness  
186 and  $\alpha$ -diversity reduced slightly the first days after the intervention, which was resolved by day  
187 14 to 28. A similar trend was observed for the richness and diversity of the WGS phageome,  
188 which consists mainly of prophages that could have been depleted with their bacterial hosts.  
189 In contrast, the richness of the VLP phageome increased slightly by day 2 in both groups,  
190 while the  $\alpha$ -diversity decreased only in the placebo group, albeit non-significant ( $p = 0.2$ ).

## 191 192 **Increase in new phages independent of the intervention**

193 To determine whether phages from the donors transferred to the recipients, we looked at the  
194 abundance of phages shared between donor and recipient. Although not significant, after FFT  
195 the VPs shared with the donor within the WGS phageome increased up to day 14 (figure 3A).  
196 For the VLP phageome we found an opposite effect, where the VPs shared with the donor  
197 decreased non-significantly after the FFT (figure 3B). The broader effect of the FFT on the  
198 phageomes was determined by analysing the abundance of new phages that appeared after  
199 the FFT within the WGS phageome (figure 3C) and within the VLP phageome (figure 3D). In  
200 both groups the abundance of new phages increased over time and although not significant,  
201 this increase was slightly higher in the FFT group, especially in the VLP phageome on day 2

202 (p = 0.2). These results seem to indicate that the phageomes were perturbed in both the  
203 placebo and FFT groups. It further shows that donor-derived phages, especially the VLPs,  
204 were either mostly immediately removed from the gut or their engraftment was balanced with  
205 the removal of pre-existing VPs shared with the donors.

206

### 207 **FFT alters the phage composition of the VLP fraction**

208 Subsequently, we looked at compositional changes within the bacteriome, WGS phageome,  
209 and VLP phageome (figure 4A). Principal response curves showed no overall effect of the FFT  
210 on any of these communities compared to placebo, except for a significantly different  
211 composition of the VLP phageome on day 2 (p=0.02). This difference in composition within  
212 the VLP phageome on day 2 was also evident from a separate principal component analysis  
213 (figure 4B, PERMANOVA p=0.028). As this pointed toward a short-term effect of the FFT, we  
214 looked more specifically into VLP communities on day 2 and found 216 VPs that were  
215 differentially abundant between the FFT and placebo groups (figure 4C and table S3).

216

217 To get a better understanding of these phages, we looked at the bacterial host species that  
218 these differentially abundant VPs can infect. We observed 10 bacterial hosts of which the  
219 phages were significantly enriched among these VPs (figure 4D). The phages infecting some  
220 of these host bacteria, like *Roseburia intestinalis* and *Bacteroides cellulosilyticus*, were  
221 present in both FFT and placebo treatment groups. But others, like *Sutterella wadsworthensis*  
222 and *Scatocola faecigallinarum*, were notably exclusively differentially abundant in one of the  
223 two treatment groups. The only host species enriched among differentially abundant VPs and  
224 more prevalent in the placebo group was *S. wadsworthensis*, a betaproteobacterium  
225 associated with gastrointestinal infections. Those more prevalent among the FFT group were  
226 taxonomically diverse, belonging to the *Bacteroidetes* (*Bacteroides fragilis* and *B.*  
227 *cellulosilyticus*), *Firmicutes* (*R. intestinalis*, *Faecousia*, *Eisenbergiella*, CAG-882 and CAG-  
228 170) and *Proteobacteria* (*S. faecigallinarum* and CAG-267).

229

### 230 **FFT induces an antagonistic phage-microbe interaction**

231 Intrigued by the presence of differentially abundant VPs two days after FFT, we determined  
232 whether the dynamics between phages and their microbial hosts had changed. For this, we  
233 linked VPs to metagenome assembled genomes (MAGs) from our WGS sequencing dataset  
234 and calculated the mean abundance change for all VP-MAG pairs belonging to a given species  
235 in a given sample. This showed opposing relationships between MAG and VP abundance in  
236 the first two days of the intervention (figure 5A): this was negatively correlated for the FFT  
237 group (R = -0.13, p = 0.005) and positively correlated in the placebo group (R = 0.17, p  
238 <0.001). These results indicated that the FFT group was dominated by virulent phage-

239 bacterium interactions, while they were more likely to be temperate or chronic in the placebo  
240 group. These effects intriguingly were less pronounced when comparing days 2 and 28 (FFT:  
241  $R = -0.043$ ,  $p = 0.24$ ; placebo:  $R = 0.12$ ,  $p = 0.004$ ; figure 5B), and completely absent when  
242 comparing days 0 and 28 (figure 5C). Thus, the overall effect of the FTT on phage-host  
243 interactions seemed pronounced but short-lived.

244

## 245 **DISCUSSION**

246 This is the first randomized controlled clinical trial in which a sterile faecal filtrate was  
247 administered to human individuals. In the present study, the FFT was well-tolerated and safe,  
248 with recipients experiencing solely mild gastrointestinal adverse effects. As the study group is  
249 small, larger studies with a longer follow-up are warranted to fully assess the safety profile of  
250 the FFT. However, compared to FMTs, an FFT depleted of living microorganisms has a lower  
251 risk of transferring unknown pathogenic bacteria<sup>27</sup>. Since FMT has a good safety profile<sup>35,36</sup>,  
252 this most likely holds true for FFTs as well. Compared to FMTs, it is relatively easier to further  
253 optimise and standardise FFTs, e.g., through lyophilization and encapsulation of faecal filtrate,  
254 as the viability of the many strict anaerobic bacteria does not have to be preserved. Such  
255 developments of FFT will ease the administration, reduce the invasiveness, and provide an  
256 option for prolonged or maintenance therapy, even in a home-setting.

257

258 While we did find a slight improvement of the glucose variability in the FFT group, expressed  
259 as the time between 3.9-10 mmol/L glucose, the FFT and placebo groups showed similar  
260 glucose excursions during the OGGT performed at day 28. Previously, an FVT in diet-induced  
261 obese mice reduced weight gain and improved blood glucose tolerance<sup>30</sup>. However, FVTs  
262 differ slightly from FFTs, with phages being more concentrated and washed to reduce bacterial  
263 debris, metabolites and antimicrobial peptides. Moreover, in this previous study, several donor  
264 phageomes were combined, resulting in a highly diverse phageome. In addition, compared to  
265 humans, microbiomes of mice are more similar due to the same housing and diet<sup>37</sup>, thereby  
266 increasing the chance of highly specific bacteriophages encountering their host and,  
267 subsequently, modulating the microbiota. In humans, improvement of insulin sensitivity after  
268 lean healthy donor FMT in individuals with MetSyn has been reported<sup>28,29</sup>. These studies had  
269 a comparable study design as present study, with the major difference being the absence of  
270 the faecal bacteria in the intervention. Although this is not a direct comparison, we speculate  
271 that, in the case of MetSyn, the beneficial bacteria transplanted during an FMT significantly  
272 contribute to the improved glucose metabolism observed.

273

274 Nevertheless, the FFT was able to alter the phage virions or VLP phageome composition on  
275 day 2 compared to the placebo, showing 216 differentially abundant VPs. By day 28 this



276 significant difference disappeared, which indicates the FFT effect was short-lived. Looking at  
277 the bacterial hosts of these phages, we found 10 host species that were significantly enriched,  
278 of which 9 were more prevalent in the FFT group. One of these bacterial hosts is the butyrate  
279 producer *Roseburia intestinalis*, which has been found to be depleted in MetSyn<sup>38,39</sup> and  
280 contributes to inflammatory signalling inhibition and intestinal barrier repair<sup>40,41</sup>. Another short-  
281 chain fatty acid producer belonging to the *Eisenbergiella* species has been associated with  
282 increased skeletal muscle mass<sup>42</sup>. *Bacteroides fragilis* has also been found to be depleted in  
283 MetSyn<sup>43,44</sup>, while *Bacteroides cellulosilyticus*, a cellulose degrader, has been associated with  
284 a healthy plant-based diet and found to be depleted in obese individuals<sup>45,46</sup>.

285

286 In addition, we speculate that the FFT induced virulent interactions between phages and their  
287 microbe hosts in the first two days after administration, while the phage-microbe interactions  
288 appeared more lysogenic/temperate in the placebo group. These results seem to indicate that  
289 either the donor phages managed to infect the bacteria from the recipient and lyse them, or  
290 that the introduction of novel donor phages induced pre-existing prophages. As the number of  
291 previously unobserved VLP VPs increased on day 2, while donor-shared VLP VPs did not, we  
292 hypothesize the latter is more likely. It could be that some non-phage element of the FFT, such  
293 as fructose<sup>47</sup> or a phage-derived peptide<sup>48</sup>, prompted integrated phages to excise from their  
294 bacterial hosts. Otherwise, it could also be that increased infection of bacteria by donor-  
295 derived phages caused lower bacterial abundance, resulting in higher phage lysis rates, in  
296 line with the piggyback the winner model of phage-host interactions<sup>49</sup>. Following this  
297 hypothesis further, growth of (some) bacterial species after the laxative treatment could have  
298 caused increased lysogeny among the phageomes in the placebo group.

299

300 Interestingly, changes in bacterial and viral diversity over time were similar between both  
301 groups. While we did observe a small, non-significant increase in the abundance of VPs  
302 shared with the donor in the WGS phageome, this abundance decreased non-significantly  
303 within the VLP phageome. This can in part be explained by the large increase in new phages  
304 within the VLP phageome (50-60%), which was bigger compared to the increase within the  
305 WGS phageome (~15%). The increase in new phages indicates that the phageome was  
306 perturbed, leading to an accelerated genomic recombination that stimulated phage evolution.  
307 However, since this happened in both groups, we hypothesize that this is, in part, an effect of  
308 the laxative pre-treatment. This laxative treatment could have removed pre-existing donor-  
309 shared VPs, and, by washing away part of the host bacteria, could have reduced the  
310 probability of donor phages infecting their host.

311

312 This study has several limitations. The small sample size and large heterogeneity within the  
313 MetSyn study population hindered identification of significant differences between the groups.  
314 The lack of a large FFT effect could also be explained by the use of the laxative pre-treatment,  
315 which reduced the number of potential hosts for the transplanted phages. In addition, we  
316 speculate that the use of laxative prior to the OGTT reduced the fasting insulin levels and  
317 associated HOMA-IR values at baseline, which was observed in both groups, independent of  
318 the intervention. Therefore, for future studies with FFT, we would highly recommend to omit  
319 this step. In addition, pooling of donor phages and matching donors and recipients, thereby  
320 increasing the diversity and likelihood of a phage-host match, could further improve the  
321 efficacy of the FFT. Due the ethical reasons, we had to keep the production of the  
322 bacteriophage transplant simple and straightforward, which is why we performed an FFT  
323 instead of an FVT in this human intervention study. Therefore, we cannot completely rule out  
324 any effect of other compounds present in the filtrate besides the phages, such as bacterial  
325 debris, metabolites and antimicrobial peptides. In line, we performed tangential flow filtration  
326 with sterile, single-use cassettes with a 0.2  $\mu\text{m}$  membrane to reduce the potential risk of cross-  
327 contamination between donors. However, not all phages may pass through these pores and  
328 a pore size of 0.45  $\mu\text{m}$  will result in higher phage titres, as has been described previously<sup>50</sup>.  
329 Finally, since we only included Dutch European subjects, the generalizability of our results to  
330 other populations is limited.

331  
332 Besides above-mentioned suggestions for future FFT studies, future research should focus  
333 on targeting specific bacteria with phages to get a better mechanistic understanding of how  
334 bacterial communities are changed upon phage predation and how these changes could affect  
335 disease phenotypes. One example of specific phages targeting pathogenic bacteria is the  
336 phage cocktail developed to treat recurrent *Clostridioides difficile* infections<sup>51</sup>. Another  
337 interesting target are the *Lactobacillaceae* that are thought to produce ethanol and thereby  
338 contribute to non-alcoholic fatty liver disease (NAFLD)<sup>52</sup>. It should be noted that such precision  
339 therapy might be very efficient at clearing a specific pathogen, but will unlikely restore any  
340 underlying microbial dysbiosis. Therefore, a combination of endogenous phages to modulate  
341 a complete microbiome should be further studied, e.g., by matching donors and recipients  
342 based on their phageome and bacteriome composition, respectively.

343  
344 In conclusion, this is a first double-blind, randomized, placebo-controlled trial in which we  
345 performed an FFT in human individuals with MetSyn. We provide evidence that gut phages  
346 from a healthy donor can be safely administered to transiently alter the gut microbiota of  
347 recipients. This study provides a critical basis for follow-up studies, which should better match  
348 donors and recipients based on their bacteriome and phageome composition.

349

## 350 **METHODS**

### 351 **Study design**

352 We set up a prospective, double-blinded, randomised, placebo-controlled intervention study  
353 that was performed in our academic hospital. After passing screening, 24 subjects with  
354 MetSyn were randomised to receive a sterile FFT from a lean healthy donor or a placebo  
355 transplant. Block randomization with stratification for age and sex was used, while both  
356 participants and researcher were blinded for the intervention. Prior to the intervention and after  
357 28 days at follow-up, subjects underwent an OGTT to assess their glucose metabolism. In  
358 addition, a week prior to until one week after intervention, subjects monitored their blood  
359 glucose using a flash glucose monitoring device (Freestyle Libre). Fecal samples were  
360 collected at multiple timepoints between baseline and follow-up to study dynamic changes in  
361 the microbiome. Finally, during every study visit a medical exam was conducted in addition to  
362 blood plasma collection to assess the safety of the intervention. Figure 1A provides a  
363 schematic overview of the study.

364

### 365 **Study subjects**

366 Study participants were all European Dutch, overweight (body mass index (BMI)  $\geq 25$  kg/m<sup>2</sup>)  
367 subjects between 18 and 65 years of age and had to meet the National Cholesterol Education  
368 Program (NCEP) criteria for the metabolic syndrome<sup>31</sup>. Main exclusion criteria were the use  
369 of any medication, illicit drug use, smoking, or alcohol abuse in the past 3 months, as well as  
370 a history of cardiovascular, gastrointestinal, or immunological disease. Table S4 summarises  
371 all in- and exclusion criteria.

372

### 373 **Donor screening**

374 Faeces donors were lean healthy European Dutch subjects who were thoroughly screened  
375 according to the guidelines of the European FMT Working Group<sup>53</sup>. Screening of potential  
376 donors was performed in a stepwise manner as previously published<sup>32</sup>. Briefly, potential  
377 donors first completed an extensive screening questionnaire. If they passed this stage, their  
378 faeces were screened for pathogenic parasites. When negative, several faecal samples were  
379 screened for presence of pathogenic bacteria, viruses, and multidrug resistant organisms  
380 (MDROs), as well as the level of calprotectin. Donors screened after May 2020 were  
381 additionally screened for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)<sup>54</sup>.  
382 In addition, blood was collected for serological testing and to screen for an abnormal liver or  
383 renal function or an impaired immunity. When donors passed this screening, they were  
384 allowed to donate faeces for a period of 6 months. Table S5 lists the specific in- and exclusion  
385 criteria for faeces donors. Every two months, active donors underwent a short rescreening,

386 which included, among others, screening for MDROs and SARS-CoV-2. In addition, before  
387 every donation, donors had to complete a shortened questionnaire to confirm their eligibility.  
388 We matched donors and recipients based on their gender and whether they have had a prior  
389 infection with cytomegalovirus or Epstein–Barr virus.

390

### 391 **Sterile faecal filtrate production and administration**

392 Production of the sterile faecal filtrate started the day before administration to the MetSyn  
393 subjects. First, 50 g of stool was collected from a screened donor, which was homogenized  
394 with 500 ml sterile saline. Large particles were filtered from the faecal suspension using double  
395 sterile gauzes. Most of the bacteria were removed in two subsequent centrifugation steps, in  
396 which the suspension was spun for 1 hour at 10.000 x g. Finally, the supernatant was filtered  
397 through a sterile 0.2 µm membrane using a tangential flow filtration device (Vivaflow 50).  
398 Production of the filtrate from donor stool was performed within 6 hours and took, on average,  
399 334 minutes (SD = 27). The filtrate was stored overnight in a fridge until administration. The  
400 production is depicted in figure S3A.

401

402 The sterile faecal filtrate was administered to the patient via a nasoduodenal tube. The day  
403 prior to the administration, subjects were asked to clean their bowel using a laxative (Klean-  
404 Prep®, Norgine B.V.), which is a standard pre-treatment for FMT procedures in our hospital.  
405 Nasoduodenal tubes were placed with the help of a Cortrak®2 enteral access system (Avanos  
406 Medical Inc.), making sure the nasoduodenal tube was correctly positioned. The faecal filtrate  
407 was slowly infused with a 60 ml syringe, on average 300 ml during a 15-20 min period. Figure  
408 S3B provides a schematic overview of the FFT procedure.

409

410 We confirmed the absence of bacteria from the faecal filtrate with a qPCR for the bacterial  
411 16S rRNA gene as previously described<sup>55</sup>, showing a 10<sup>5</sup>-fold decrease in bacterial DNA  
412 (figure S3C). We further confirmed this by culturing of the faecal filtrate using Biosart® 100  
413 monitors (Sartorius). 100 ml of faecal filtrate was filtered and the cellulose nitrate membranes  
414 were incubated on petri dishes with Columbia agar + 5% sheep blood (bioMérieux) for two  
415 days at 37°C under both aerobic and anaerobic conditions. We did not observe any colony-  
416 forming units in 100 ml of faecal filtrate (results not shown).

417

### 418 **Outcomes**

419 The primary outcome was change in glucose metabolism, as determined by the total area  
420 under the curve (AUC) for glucose excursion during the OGTT. Secondary outcomes related  
421 to glucose metabolism were changes in fasting glucose, insulin, HOMA-IR, and HbA1c  
422 between baseline and follow-up after 28 days, as well as changes in glucose variability

423 measured by CGM a week before and after intervention. Other secondary outcomes were the  
424 dynamic changes in gut bacteriome and virome populations following FFT or placebo  
425 intervention and the comparison of phage composition between lean donors and subjects with  
426 MetSyn. Finally, we assessed the safety of the FFT as determined by the occurrence of  
427 (serious) adverse events, physical exam, and several blood parameters for renal and liver  
428 function and inflammation.

429

### 430 **Sample size calculation**

431 Based on previous data from our group in which individuals with MetSyn received an FMT<sup>28,29</sup>,  
432 and the hypothesis that a faecal phage transplant can be equally effective as a traditional  
433 FMT<sup>25–27,30</sup>, we assumed a 15% improvement in glucose tolerance upon FFT. With a two-sided  
434 5% significance level and a power of 80%, a sample size of 12 patients per group was  
435 necessary, given an anticipated dropout rate of 10%. To recruit 24 individuals with MetSyn,  
436 we anticipated a 12-month inclusion period.

437

### 438 **Oral glucose tolerance test**

439 For the OGTT, overnight fasted subjects ingested a standardized glucose solution (75g).  
440 Blood was drawn from an intravenous catheter at baseline and 15, 30, 45, 60, 90, and 120  
441 minutes after ingestion. Both blood serum and plasma were aliquoted and stored at -80°C.  
442 From these aliquots we measured glucose and C-peptide. In addition, additional blood  
443 samples collected at baseline were used to measure fasted glucose and insulin, HbA1c and  
444 the clinical safety parameters for renal/liver function and inflammation.

445

### 446 **Continuous glucose monitoring**

447 To reduce the study burden and prevent daily finger pricks, we used a continuous glucose  
448 monitoring device (Freestyle Libre) to monitor blood glucose, which allowed subjects to  
449 perform all normal activities while wearing the sensor. Subjects were taught to subcutaneously  
450 implant the CGM sensor and were instructed to extract the data from the sensor at least every  
451 8 hours. One week prior to the intervention subjects started to monitor their glucose until one  
452 week after the intervention. Compliance among participants was good, with a median 100%  
453 (range 76-100%) of data correctly collected, during a median period of 14 (range 11-27) days  
454 with a median 1350 (range 1043-2617) sensor readings. During that same period, participants  
455 were asked to record their diet using an online food diary (Eetmeter from the  
456 Voedingscentrum)<sup>56</sup>. At the follow-up visit, data from the CGM scanner were exported and  
457 analysed with a previously published R package for CGM data analysis<sup>57</sup>.

458

### 459 **Faeces collection**

460 The day before the intervention and 2, 4, 7, 14, and 28 days thereafter, subjects were asked  
461 to collect several faecal samples. Faeces were collected by participant in stool collection  
462 tubes, which were directly stored in a freezer at home inside a safety bag. In addition,  
463 participants registered the time, date, and consistency of the collected faeces according to the  
464 Bristol Stool Chart. At the baseline and follow-up visits, these faecal samples were transported  
465 to the hospital frozen, where they were directly stored at -80°C until the end of the study.

466

### 467 **Bacteriome and virome sequencing**

468 To study the bacteriome and virome, we performed whole genome shotgun (WGS)  
469 sequencing. From the stored frozen faeces samples, total genomic DNA was extracted using  
470 a repeated bead beating method as described previously<sup>33</sup>. Libraries for shotgun  
471 metagenomic sequencing were prepared using the NEBNext Ultra II Library prep kit (New  
472 England Biolabs Cat#E7645L) and sequenced on an Illumina HiSeq instrument with 150 bp  
473 paired-end reads and 6 Gb data/sample at Novogene (Cambridge, United Kingdom). Figure  
474 S3D summarises the sequencing and bioinformatics pipeline used.

475

### 476 **VLP sequencing**

477 To study phage virions, we isolated the faecal VLP fraction and sequenced dsDNA phages as  
478 previously described<sup>19</sup>. Briefly, the VLPs were extracted from 500 mg of faeces using high-  
479 speed centrifugation followed by filtration through a 0.45 µm membrane. Any free-DNA debris  
480 was digested prior to lysing the VLPs, whereafter the DNA was purified using a two-step  
481 phenol/chloroform extraction protocol. Finally, the DNA was purified using the DNeasy  
482 Blood&Tissue kit (Qiagen Cat#69506) according to the manufacturer's protocol. Library  
483 preparation was done with the NEBNext Ultra II FS DNA library prep kit (New England Biolabs  
484 Cat#E7805L) and the NEBNext Multiplex Oligos for Illumina dual indexes (New England  
485 Biolabs Cat#E7600S) according to manufacturer's instructions. Quality and concentration of  
486 the VLP libraries were assessed with the Qubit dsDNA HS kit (ThermoFisher Cat#Q32854)  
487 and with the Agilent High Sensitivity D5000 ScreenTape system (Agilent Technologies).  
488 Libraries were sequenced using 2x150 bp paired-end chemistry on an Illumina NovaSeq 6000  
489 platform with the S4 Reagent Kit v1.5, 300 cycles (Illumina Cat#20028312).

490

### 491 **Sequence assembly**

492 Sequencing resulted in an average of  $21.7 \pm 3.5$  M reads per WGS sample (median: 22.4 M  
493 reads), and  $23.6 \pm 18.3$  M per VLP sample (median: 18.1 M reads). Before assembly, reads  
494 belonging to the same participant were concatenated. Adapter sequence removal and read  
495 trimming were performed with fastp v0.23.2 (option `-detect_adapter_for_pe`)<sup>58</sup>. As previously  
496 recommended<sup>59</sup>, reads were then error corrected with tadpole (options `mode=correct`, `ecc=t`,

497 prefilter=2), and deduplicated with clumpify (options dedupe=t, optical=t, dupedist=12000),  
498 both from bbmap v38.90 (<https://jgi.doe.gov/data-and-tools/bbtools>). High-quality reads from  
499 WGS samples were then cross-assembled per participant using metaSPAdes v3.15.5<sup>60</sup>  
500 (option --only-assembler). Due to their greater complexity, VLP reads were assembled with  
501 MEGAHIT v1.2.9<sup>61</sup>.

502

### 503 **Viral sequence recognition and clustering**

504 To identify viral sequences among the WGS and VLP assemblies, contigs longer than 5000  
505 bp were analyzed with virsorter v2.2.3<sup>62</sup> (option --exclude-lt2gene) and checkv v1.0.1<sup>63</sup>.  
506 Contigs were taken to be of viral origin if at least one of the following criteria was true: checkv  
507 identified at least one viral gene, VirSorter2 gave a score of at least 0.95, VirSorter2 identified  
508 at least 2 viral hallmark genes, checkv identified no viral or bacterial genes. The resulting viral  
509 sequences were then deduplicated at 100% with bbdupes from bbmap v38.90 (option  
510 minidentity=100). This resulted in a non-redundant database of 50,724 viral contigs, which  
511 were subsequently clustered at 90% average nucleotide identity (ANI) into viral populations  
512 (VPs) using blastn all-vs-all searches with BLAST v2.12.0+<sup>64</sup>. The longest contigs in each VP  
513 were further clustered into viral clusters (VCs) by vContact2 v0.11.3<sup>65</sup>. Since the conclusions  
514 of the analyses were identical regardless of whether they were performed with VPs or VCs,  
515 only VP-level analyses were reported.

516

### 517 **Viral read depth determination**

518 Viral relative abundance was determined by mapping high-quality reads from each sample  
519 (i.e., one mapping per participant and time-point) against non-redundant viral sequences with  
520 bowtie2 v2.4.2<sup>66</sup>. Following earlier recommendations<sup>67</sup>, contigs were considered to be present  
521 if at least 75% of their bases were covered by at least 1 read mapped with over 90% ANI. To  
522 determine this, reads mapping with less than 90% ANI were removed from alignments with  
523 coverm filter v0.6.1 (option --min-read-percent-identity 90,  
524 <https://github.com/wwood/CoverM>), and coverage was determined with bedtools genomecov  
525 v2.27.1<sup>68</sup> (option -max 1). Read counts per contigs were then determined with samtools  
526 idxstats v1.15.1<sup>69</sup>, and those with a horizontal coverage of <75% were set to zero. Read counts  
527 and contig lengths were summed per VP, and reads per kilobase per million mapped reads  
528 (RPKM) values were calculated to take differential contig lengths.

529

### 530 **Bacterial community profiling and binning**

531 Bacterial population compositions of WGS samples were profiled per participant and time point  
532 with mOTUs v3.0.3<sup>70</sup>. Binning contigs into metagenome assembled genomes (MAGs) was  
533 done per participant. First, high quality reads from each time-point were mapped to cross-

534 assembled contigs of at least 2500 bp with bowtie2 v2.4.2. Read depth tables were then  
535 constructed with jgi\_summarize\_bam\_contig\_depths v2.15, and contigs were binned with  
536 metabat2 v2:2.15<sup>71</sup>. Completion and contamination of putative MAGs were then determined  
537 using checkm v1.2.1<sup>72</sup> and, like was previously done<sup>73</sup>, MAGs were considered for further  
538 analysis if completeness - (5 x contamination) was at least 50. Taxonomy of such MAGs was  
539 determined with GTDB-Tk v2.1.1<sup>74</sup> using the R207-v2 database package. This resulted in a  
540 database of 3011 MAGs with an assigned taxonomy.

541

#### 542 **Determining phage-host links**

543 Viral sequences were linked to bacterial MAGs in two ways. Firstly, if a viral contig was  
544 contained within a MAG, it was considered to be a prophage. Secondly, viral contigs were  
545 linked to MAGs using CRISPR spacer hits. For this, CRISPR spacer arrays were identified  
546 among MAGs using CRISPCasFinder v4.2.20<sup>75</sup>. CRISPR spacers between 20 and 30 bp in  
547 length were then matched to viral contigs through a blastn search with BLAST v2.12.0+  
548 (options -task blastn-short). Spacer hits were finally filtered for those with 5 or fewer  
549 mismatches.

550

#### 551 **Statistical analyses**

552 Richness,  $\alpha$ -diversities, principal component analysis (PCA), and principal response curves  
553 (PRC) were all calculated with the vegan R package<sup>76</sup>. For richness and  $\alpha$ -diversity RPKM  
554 values were used, while PCAs and PRCs used centered log ratio (clr)-transformed data so as  
555 to account for the compositionality of the data<sup>77</sup>. Before clr-transformation, VPs of low  
556 abundance and prevalence were removed by removing those with total RPKM of <100 over  
557 all samples, as well as those with RPKM values of >20 in less than 10% of samples.  
558 Significance levels of PCAs were calculated with a permutational analysis of variance  
559 (PERMANOVA) test, as implemented in the vegan R package v2.6-4 and were controlled for  
560 age and sex. For the PRC-analysis, the permutest function was used to calculate significance.  
561 Both PERMANOVA and permutest used 1000 permutations. p-values were adjusted for  
562 multiple testing using the Benjamini-Hochberg approach where necessary. General linear  
563 models were constructed with the glmmPQL function from the MASS R package v7.3-58.1  
564 with the age, sex, day, group, and day:group as fixed effects and participants as random effect.

565

#### 566 **Differential abundance**

567 Differential abundance of VPs among VLP samples on day 2 was determined with ANCOM-  
568 BC v1.2.2<sup>78</sup>. Input of ANCOM-BC consisted of the raw read counts summed per VP in each  
569 sample, because this method has its own internal data normalizations to account estimated  
570 sample fractions. ANCOM-BC was run on VPs with at least 20 reads reported in at least 10%



571 of samples. To account for the relatively small sample sizes, structural zero discovery was  
572 turned on but the usage of the asymptotic lower bound turned off<sup>78</sup>. Differential abundance  
573 was corrected for the effects of age and sex. The number of differentially abundant (DA) VPs  
574 was then determined per host species. Enrichment of host species among DA VPs was  
575 calculated using a hypergeometric test as implemented in the phyper R function, with the  
576 number of DA VPs infecting a given species-1 as  $q$ , the total number of VPs in the dataset  
577 infecting the same species as  $m$ , the total number of VPs with host- $m$  as  $n$ , the total number  
578 of DA VPs as  $k$ , and lower.tail set to FALSE.

579

### 580 **Phage-host interactions**

581 To determine the dynamics of phage-bacterium interaction across the entire population, the  
582 change in relative abundance between days 0 and 2, 2 and 28, and 0 and 28 were determined  
583 for all VPs with a host and all MAGs with a known phage. The resulting values were then  
584 averaged for both VPs and MAGs at the species level, after which Spearman correlation  
585 coefficients were calculated.

586

### 587 **Supplementary material**

588 Figure S1: Recruitment of individuals with MetSyn and stool donors.

589 Figure S2: Principal component analyses of viral populations.

590 Figure S3: Methods of FFT production and sequencing pipeline.

591 Table S1: Baseline dietary intake of participants.

592 Table S2: Results from the continuous glucose monitoring devices.

593 Table S3: Differentially abundant viral populations between the FFT and placebo groups.

594 Table S4: In- and exclusion criteria for study participants.

595 Table S5: In- and exclusion criteria for faeces donors.

596

### 597 **Acknowledgements**

598 We want to thank Aline Fenneman, Klaartje de Bruin and Melhandanie Benard for their help  
599 with stool donor recruitment and screening. In addition, we thank Veera Houttu, Ulrika  
600 Boulund, Kim Dzobo and Torsten Scheithauer for performing the randomization to guarantee  
601 blinding of the investigator and volunteer. We would also like to thank Ana Gerós, Yannick  
602 van Schajik and Stephanie Handana for their help in setting up the faecal filtrate production  
603 and optimisation. We are grateful for the help of the gastroenterology department of the  
604 Amsterdam UMC, location AMC, for their support with the Cortrak®2 enteral access system.  
605 We also like to acknowledge the Microbiota Centre Amsterdam for their help with the DNA  
606 isolation of the faecal samples and the Genomics core of the Amsterdam UMC, location

607 AMC, for their advice on the whole genome shotgun sequencing. Finally, we are most  
608 grateful for the volunteers who participated in this clinical pilot study.

609

### 610 **Author contributions**

611 HH and MN conceived the research idea and designed the study; KW performed the clinical  
612 study; KW and TPMS processed the samples in the laboratory; PAdJ, KW and IA performed  
613 data analysis; KW and PAdJ wrote the first draft of the manuscript; All authors contributed to  
614 manuscript revision, read and approved the submitted version.

615

### 616 **Funding**

617 KW was supported by a Novo Nordisk Foundation CAMIT grant 2018 (28232) to MN and a  
618 Diabetes II Breakthrough grant (459001008) to HH. PAdJ en TPMS were supported by DDRF  
619 Senior fellowship (2019.82.004) to HH. IA was supported through a Le Ducq consortium grant  
620 (17CVD01) to MN. MN was supported by a personal ZONMW-VICI grant 2020  
621 (09150182010020) and a Le Ducq consortium grant (17CVD01). HH was supported by a  
622 Senior Fellowship of the Dutch Diabetes Research Foundation (2019.82.004). The funders  
623 had no role in the study design, the collection, analysis, and interpretation of data, the writing  
624 of the report, and the decision to submit the article for publication.

625

### 626 **Competing interests**

627 MN is founder and scientific advisors of Caelus Health, however none of this bears any  
628 relevance to the content of the current paper. KW, PAdJ, TPMS, IA, EMK, and HH report no  
629 conflict of interest.

630

### 631 **Patient and public involvement statement**

632 Patients were involved in the assessment of the grant proposals for this study by the Dutch  
633 Diabetes Research Foundation (Diabetes II Breakthrough grant (459001008) and Senior  
634 Fellowship (2019.82.004)). Moreover, the patient panel advised on the patient burden of the  
635 clinical study. Moreover, patients were involved in the ethical approval of this study (as part of  
636 the ethics committee). Once the trial has been published, participants are informed of the  
637 results in a letter suitable for a non-specialist audience.

638

### 639 **Ethics approval and informed consent statement**

640 This study involves human participants and was approved by the Medical Research Ethics  
641 Committee Academic Medical Center Amsterdam. Both participants and faeces donors gave  
642 informed consent to participate in the study before taking part. The study was registered at  
643 the Dutch National Trial Register (NTR) under NL8289. This registry does not exist anymore

644 and all data has been added unaltered to the Dutch Trial Register (LTR) under  
645 <https://clinicaltrialregister.nl/en/trial/26916>. While these data are automatically included in the  
646 International Clinical Trial Registry Platform (ICTRP), thereby fulfilling the requirement of  
647 prospective registration as required by the International Committee of Medical Journal Editors  
648 (ICMJE), it was unfortunately no longer possible to adjust the data.

649

#### 650 **Data availability statement**

651 The sequencing data generated in this study have been deposited in the European  
652 Nucleotide Archive database under accession code: PRJEB60691. The data are freely  
653 available without restriction.

654

#### 655 **Code availability statement**

656 All used software is freely available. In the methods section the specific versions and  
657 settings are described. No custom software was developed for this project.

658

#### 659 **References**

- 660 1. Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. *J*  
661 *Clin Invest*. 2019 Oct 1;129(10):4050–7.
- 662 2. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and  
663 its associated pathologies. *Obes Rev*. 2015 Jan;16(1):1–12.
- 664 3. Gurka MJ, Guo Y, Filipp SL, DeBoer MD. Metabolic syndrome severity is significantly  
665 associated with future coronary heart disease in Type 2 diabetes. *Cardiovasc*  
666 *Diabetol*. 2018 Jan 19;17(1):17.
- 667 4. Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van  
668 Raalte DH, et al. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity  
669 and Type 2 Diabetes. *Front Immunol*. 2020;11:571731.
- 670 5. Ussar S, Griffin NW, Bezy O, Fujisaka S, Vienberg S, Softic S, et al. Interactions  
671 between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to  
672 Obesity and Metabolic Syndrome. *Cell Metab*. 2015 Sep;22(3):516–30.
- 673 6. Zuppi M, Hendrickson HL, O'Sullivan JM, Vatanen T. Phages in the Gut Ecosystem.  
674 *Front Cell Infect Microbiol*. 2021;11(January):822562.
- 675 7. Shkoporov AN, Hill C. Bacteriophages of the Human Gut: The “Known Unknown” of  
676 the Microbiome. *Cell Host Microbe* [Internet]. 2019;25(2):195–209. Available from:  
677 <https://doi.org/10.1016/j.chom.2019.01.017>
- 678 8. Gregory AC, Zablocki O, Zayed AA, Howell A, Bolduc B, Sullivan MB. The Gut Virome  
679 Database Reveals Age-Dependent Patterns of Virome Diversity in the Human Gut.  
680 *Cell Host Microbe*. 2020 Nov 11;28(5):724-740.e8.

- 681 9. Marbouty M, Thierry A, Millot GA, Koszul R. MetaHiC phage-bacteria infection  
682 network reveals active cycling phages of the healthy human gut. *Elife*. 2021 Feb  
683 26;10.
- 684 10. de Jonge PA, Nobrega FL, Brouns SJJ, Dutilh BE. Molecular and Evolutionary  
685 Determinants of Bacteriophage Host Range. *Trends Microbiol*. 2019 Jan;27(1):51–63.
- 686 11. Breitbart M, Bonnain C, Malki K, Sawaya NA. Phage puppet masters of the marine  
687 microbial realm. *Nat Microbiol*. 2018 Jul;3(7):754–66.
- 688 12. Kuzyakov Y, Mason-Jones K. Viruses in soil: Nano-scale undead drivers of microbial  
689 life, biogeochemical turnover and ecosystem functions. *Soil Biol Biochem*. 2018  
690 Dec;127:305–17.
- 691 13. Gogokhia L, Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, et al.  
692 Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and  
693 Colitis. *Cell Host Microbe*. 2019;25(2):285-299.e8.
- 694 14. Norman JM, Handley SA, Baldrige MT, Droit L, Liu CY, Keller BC, et al. Disease-  
695 specific alterations in the enteric virome in inflammatory bowel disease. *Cell*. 2015  
696 Jan 29;160(3):447–60.
- 697 15. Adiliaghdam F, Amatullah H, Digumarthi S, Saunders TL, Rahman R-U, Wong LP, et  
698 al. Human enteric viruses autonomously shape inflammatory bowel disease  
699 phenotype through divergent innate immunomodulation. *Sci Immunol*. 2022 Apr  
700 8;7(70):eabn6660.
- 701 16. Nakatsu G, Zhou H, Wu WKK, Wong SH, Coker OO, Dai Z, et al. Alterations in  
702 Enteric Virome Are Associated With Colorectal Cancer and Survival Outcomes.  
703 *Gastroenterology*. 2018 Aug;155(2):529-541.e5.
- 704 17. Chen Q, Ma X, Li C, Shen Y, Zhu W, Zhang Y, et al. Enteric Phageome Alterations in  
705 Patients With Type 2 Diabetes. *Front Cell Infect Microbiol*. 2020;10:575084.
- 706 18. Manrique P, Zhu Y, van der Oost J, Herrema H, Nieuwdorp M, de Vos WM, et al. Gut  
707 bacteriophage dynamics during fecal microbial transplantation in subjects with  
708 metabolic syndrome. *Gut Microbes*. 2021;13(1):1–15.
- 709 19. de Jonge PA, Wortelboer K, Scheithauer TPM, van den Born B-JH, Zwinderman AH,  
710 Nobrega FL, et al. Gut virome profiling identifies a widespread bacteriophage family  
711 associated with metabolic syndrome. *Nat Commun*. 2022;13(1):3594.
- 712 20. Hsu BB, Gibson TE, Yeliseyev V, Liu Q, Lyon L, Bry L, et al. Dynamic Modulation of  
713 the Gut Microbiota and Metabolome by Bacteriophages in a Mouse Model. *Cell Host*  
714 *Microbe* [Internet]. 2019;25(6):803-814.e5. Available from:  
715 <https://doi.org/10.1016/j.chom.2019.05.001>
- 716 21. Manohar P, Tamhankar AJ, Lundborg CS, Nachimuthu R. Therapeutic  
717 Characterization and Efficacy of Bacteriophage Cocktails Infecting *Escherichia coli*,

- 718 Klebsiella pneumoniae, and Enterobacter Species. *Front Microbiol.* 2019;10:574.
- 719 22. Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, et al. Synergy  
720 between the Host Immune System and Bacteriophage Is Essential for Successful  
721 Phage Therapy against an Acute Respiratory Pathogen. *Cell Host Microbe.* 2017 Jul  
722 12;22(1):38-47.e4.
- 723 23. Galtier M, De Sordi L, Maura D, Arachchi H, Volant S, Dillies M-A, et al.  
724 Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low  
725 impact on microbiota composition. *Environ Microbiol.* 2016 Jul 28;18(7):2237–45.
- 726 24. Mai V, Ukhanova M, Reinhard MK, Li M, Sulakvelidze A. Bacteriophage  
727 administration significantly reduces Shigella colonization and shedding by Shigella-  
728 challenged mice without deleterious side effects and distortions in the gut microbiota.  
729 *Bacteriophage.* 2015;5(4):e1088124.
- 730 25. Lin DM, Koskella B, Ritz NL, Lin D, Carroll-Portillo A, Lin HC. Transplanting Fecal  
731 Virus-Like Particles Reduces High-Fat Diet-Induced Small Intestinal Bacterial  
732 Overgrowth in Mice. *Front Cell Infect Microbiol.* 2019;9(October):1–11.
- 733 26. Draper LA, Ryan FJ, Dalmasso M, Casey PG, McCann A, Velayudhan V, et al.  
734 Autochthonous faecal viral transfer (FVT) impacts the murine microbiome after  
735 antibiotic perturbation. *BMC Biol.* 2020;18(1):173.
- 736 27. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al.  
737 Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile  
738 Infection. *Gastroenterology* [Internet]. 2017;152(4):799–811. Available from:  
739 <http://dx.doi.org/10.1053/j.gastro.2016.11.010>
- 740 28. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, et al.  
741 Transfer of intestinal microbiota from lean donors increases insulin sensitivity in  
742 individuals with metabolic syndrome. *Gastroenterology.* 2012;143(4):913-916.e7.
- 743 29. Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra A V., Udayappan SD, et al.  
744 Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is  
745 Driven by Baseline Intestinal Microbiota Composition. *Cell Metab.* 2017 Oct  
746 3;26(4):611-619.e6.
- 747 30. Rasmussen TS, Mentzel CMJ, Kot W, Castro-Mejía JL, Zuffa S, Swann JR, et al.  
748 Faecal virome transplantation decreases symptoms of type 2 diabetes and obesity in  
749 a murine model. *Gut.* 2020 Dec 12;69(12):2122–30.
- 750 31. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al.  
751 Diagnosis and management of the metabolic syndrome: an American Heart  
752 Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation.*  
753 2005 Oct 25;112(17):2735–52.
- 754 32. Bénard M V., de Bruijn CMA, Fenneman AC, Wortelboer K, Zeevenhoven J, Rethans

- 755 B, et al. Challenges and costs of donor screening for fecal microbiota  
756 transplantations. *PLoS One*. 2022;17(10):e0276323.
- 757 33. Deschasaux M, Bouter KE, Prodan A, Levin E, Groen AK, Herrema H, et al. Depicting  
758 the composition of gut microbiota in a population with varied ethnic origins but shared  
759 geography. *Nat Med*. 2018;24(10):1526–31.
- 760 34. Gregory AC, Zayed AA, Conceição-Neto N, Temperton B, Bolduc B, Alberti A, et al.  
761 Marine DNA Viral Macro- and Microdiversity from Pole to Pole. *Cell*. 2019 May  
762 16;177(5):1109-1123.e14.
- 763 35. Li Y-T, Cai H-F, Wang Z-H, Xu J, Fang J-Y. Systematic review with meta-analysis:  
764 long-term outcomes of faecal microbiota transplantation for *Clostridium difficile*  
765 infection. *Aliment Pharmacol Ther*. 2016 Feb;43(4):445–57.
- 766 36. Moayyedi P, Yuan Y, Baharath H, Ford AC. Faecal microbiota transplantation for  
767 *Clostridium difficile*-associated diarrhoea: a systematic review of randomised  
768 controlled trials. *Med J Aust*. 2017 Aug 21;207(4):166–72.
- 769 37. Nguyen TLA, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for  
770 human gut microbiota research? *Dis Model Mech*. 2015 Jan;8(1):1–16.
- 771 38. Qin Q, Yan S, Yang Y, Chen J, Li T, Gao X, et al. A Metagenome-Wide Association  
772 Study of the Gut Microbiome and Metabolic Syndrome. *Front Microbiol*.  
773 2021;12:682721.
- 774 39. Zhang C, Ma K, Nie K, Deng M, Luo W, Wu X, et al. Assessment of the safety and  
775 probiotic properties of *Roseburia intestinalis*: A potential “Next Generation Probiotic”.  
776 *Front Microbiol*. 2022;13:973046.
- 777 40. Zhao C, Bao L, Qiu M, Wu K, Zhao Y, Feng L, et al. Commensal cow *Roseburia*  
778 reduces gut-dysbiosis-induced mastitis through inhibiting bacterial translocation by  
779 producing butyrate in mice. *Cell Rep*. 2022 Nov 22;41(8):111681.
- 780 41. Ruan G, Chen M, Chen L, Xu F, Xiao Z, Yi A, et al. *Roseburia intestinalis* and Its  
781 Metabolite Butyrate Inhibit Colitis and Upregulate TLR5 through the SP3 Signaling  
782 Pathway. *Nutrients*. 2022 Jul 25;14(15).
- 783 42. Sugimura Y, Kanda A, Sawada K, Wai KM, Tanabu A, Ozato N, et al. Association  
784 between Gut Microbiota and Body Composition in Japanese General Population: A  
785 Focus on Gut Microbiota and Skeletal Muscle. *Int J Environ Res Public Health*. 2022  
786 Jun 17;19(12).
- 787 43. Haro C, Garcia-Carpintero S, Alcalá-Díaz JF, Gomez-Delgado F, Delgado-Lista J,  
788 Perez-Martinez P, et al. The gut microbial community in metabolic syndrome patients  
789 is modified by diet. *J Nutr Biochem*. 2016 Jan;27:27–31.
- 790 44. Ermolenko E, Kotyleva M, Kotrova A, Tichonov S, Lavrenova N, Voropaeva L, et al.  
791 Consortium of Indigenous Fecal Bacteria in the Treatment of Metabolic Syndrome.

- 792 Microorganisms. 2022 Aug 5;10(8).
- 793 45. Li Y, Wang DD, Satija A, Ivey KL, Li J, Wilkinson JE, et al. Plant-Based Diet Index and  
794 Metabolic Risk in Men: Exploring the Role of the Gut Microbiome. *J Nutr*. 2021 Sep  
795 4;151(9):2780–9.
- 796 46. Chen H, Tang N, Ye Q, Yu X, Yang R, Cheng H, et al. Alternation of the gut  
797 microbiota in metabolically healthy obesity: An integrated multiomics analysis. *Front*  
798 *Cell Infect Microbiol*. 2022;12:1012028.
- 799 47. Oh J-H, Alexander LM, Pan M, Schueler KL, Keller MP, Attie AD, et al. Dietary  
800 Fructose and Microbiota-Derived Short-Chain Fatty Acids Promote Bacteriophage  
801 Production in the Gut Symbiont *Lactobacillus reuteri*. *Cell Host Microbe*. 2019 Feb  
802 13;25(2):273-284.e6.
- 803 48. Erez Z, Steinberger-Levy I, Shamir M, Doron S, Stokar-Avihail A, Peleg Y, et al.  
804 Communication between viruses guides lysis-lysogeny decisions. *Nature*. 2017 Jan  
805 26;541(7638):488–93.
- 806 49. Silveira CB, Rohwer FL. Piggyback-the-Winner in host-associated microbial  
807 communities. *NPJ biofilms microbiomes*. 2016;2:16010.
- 808 50. Castro-Mejía JL, Muhammed MK, Kot W, Neve H, Franz CMAP, Hansen LH, et al.  
809 Optimizing protocols for extraction of bacteriophages prior to metagenomic analyses  
810 of phage communities in the human gut. *Microbiome*. 2015 Nov 17;3:64.
- 811 51. Fujimoto K, Uematsu S. Phage therapy for *Clostridioides difficile* infection. *Front*  
812 *Immunol*. 2022;13:1057892.
- 813 52. Meijnikman AS, Davids M, Herrema H, Aydin O, Tremaroli V, Rios-Morales M, et al.  
814 Microbiome-derived ethanol in nonalcoholic fatty liver disease. *Nat Med*. 2022  
815 Oct;28(10):2100–6.
- 816 53. Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, et al.  
817 European consensus conference on faecal microbiota transplantation in clinical  
818 practice. *Gut*. 2017 Apr;66(4):569–80.
- 819 54. Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, et al. Reorganisation of  
820 faecal microbiota transplant services during the COVID-19 pandemic. *Gut*. 2020  
821 Sep;69(9):1555–63.
- 822 55. Jian C, Luukkonen P, Yki-Järvinen H, Salonen A, Korpela K. Quantitative PCR  
823 provides a simple and accessible method for quantitative microbiota profiling. *PLoS*  
824 *One*. 2020;15(1):e0227285.
- 825 56. Stichting Voedingscentrum Nederland. Eetmeter [Internet]. 2023 [cited 2023 Jan 16].  
826 Available from: <https://mijn.voedingscentrum.nl/nl/eetmeter/>
- 827 57. Attaye I, van der Vossen EWJ, Mendes Bastos DN, Nieuwdorp M, Levin E.  
828 Introducing the Continuous Glucose Data Analysis (CGDA) R Package: An Intuitive

- 829 Package to Analyze Continuous Glucose Monitoring Data. *J Diabetes Sci Technol.*  
830 2022 May;16(3):783–5.
- 831 58. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.  
832 *Bioinformatics.* 2018 Sep 1;34(17):i884–90.
- 833 59. Roux S, Trubl G, Goudeau D, Nath N, Couradeau E, Ahlgren NA, et al. Optimizing de  
834 novo genome assembly from PCR-amplified metagenomes. *PeerJ.* 2019;7:e6902.
- 835 60. Nurk S, Meleshko D, Korobeynikov A, Pevzner PA. metaSPAdes: a new versatile  
836 metagenomic assembler. *Genome Res.* 2017 May;27(5):824–34.
- 837 61. Li D, Liu C-M, Luo R, Sadakane K, Lam T-W. MEGAHIT: an ultra-fast single-node  
838 solution for large and complex metagenomics assembly via succinct de Bruijn graph.  
839 *Bioinformatics.* 2015 May 15;31(10):1674–6.
- 840 62. Guo J, Bolduc B, Zayed AA, Varsani A, Dominguez-Huerta G, Delmont TO, et al.  
841 *VirSorter2: a multi-classifier, expert-guided approach to detect diverse DNA and RNA*  
842 *viruses. Microbiome.* 2021 Feb 1;9(1):37.
- 843 63. Nayfach S, Camargo AP, Schulz F, Eloë-Fadrosh E, Roux S, Kyrpides NC. CheckV  
844 assesses the quality and completeness of metagenome-assembled viral genomes.  
845 *Nat Biotechnol.* 2021 May;39(5):578–85.
- 846 64. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al.  
847 *BLAST+: architecture and applications. BMC Bioinformatics.* 2009 Dec 15;10:421.
- 848 65. Bin Jang H, Bolduc B, Zablocki O, Kuhn JH, Roux S, Adriaenssens EM, et al.  
849 *Taxonomic assignment of uncultivated prokaryotic virus genomes is enabled by gene-*  
850 *sharing networks. Nat Biotechnol.* 2019 Jun;37(6):632–9.
- 851 66. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient  
852 alignment of short DNA sequences to the human genome. *Genome Biol.*  
853 2009;10(3):R25.
- 854 67. Roux S, Emerson JB, Eloë-Fadrosh EA, Sullivan MB. Benchmarking viromics: an in  
855 silico evaluation of metagenome-enabled estimates of viral community composition  
856 and diversity. *PeerJ.* 2017;5:e3817.
- 857 68. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic  
858 features. *Bioinformatics.* 2010 Mar 15;26(6):841–2.
- 859 69. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years  
860 of SAMtools and BCFtools. *Gigascience.* 2021 Feb 16;10(2).
- 861 70. Milanese A, Mende DR, Paoli L, Salazar G, Ruscheweyh H-J, Cuenca M, et al.  
862 *Microbial abundance, activity and population genomic profiling with mOTUs2. Nat*  
863 *Commun.* 2019 Mar 4;10(1):1014.
- 864 71. Kang DD, Li F, Kirton E, Thomas A, Egan R, An H, et al. MetaBAT 2: an adaptive  
865 binning algorithm for robust and efficient genome reconstruction from metagenome



- 866 assemblies. PeerJ. 2019;7:e7359.
- 867 72. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM: assessing  
868 the quality of microbial genomes recovered from isolates, single cells, and  
869 metagenomes. *Genome Res.* 2015 Jul;25(7):1043–55.
- 870 73. Parks DH, Rinke C, Chuvochina M, Chaumeil P-A, Woodcroft BJ, Evans PN, et al.  
871 Recovery of nearly 8,000 metagenome-assembled genomes substantially expands  
872 the tree of life. *Nat Microbiol.* 2017 Nov;2(11):1533–42.
- 873 74. Chaumeil P-A, Mussig AJ, Hugenholtz P, Parks DH. GTDB-Tk: a toolkit to classify  
874 genomes with the Genome Taxonomy Database. *Bioinformatics.* 2019 Nov  
875 15;36(6):1925–7.
- 876 75. Couvin D, Bernheim A, Toffano-Nioche C, Touchon M, Michalik J, Néron B, et al.  
877 CRISPRCasFinder, an update of CRISRFinder, includes a portable version,  
878 enhanced performance and integrates search for Cas proteins. *Nucleic Acids Res.*  
879 2018 Jul 2;46(W1):W246–51.
- 880 76. Dixon P. VEGAN, a package of R functions for community ecology. *J Veg Sci.* 2003  
881 Dec 9;14(6):927–30.
- 882 77. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome Datasets Are  
883 Compositional: And This Is Not Optional. *Front Microbiol.* 2017;8:2224.
- 884 78. Lin H, Peddada S Das. Analysis of compositions of microbiomes with bias correction.  
885 *Nat Commun.* 2020 Jul 14;11(1):3514.

886

## 887 **Figures and tables**

888 **Figure 1: A)** Overview of the study. **B)** Glucose excursions during the oral glucose tolerance  
889 test. One person who was randomized to the FFT group had progressed to type 2 diabetes,  
890 which was not apparent at the time of screening. **C)** Total area under the curve (AUC) for  
891 glucose and **D)** for C-peptide did not significantly differ between the groups. Within both groups  
892 there was a small increase in glucose AUC between day 0 and 28, which was nominal  
893 significant within the FFT group, although this significance disappeared after correction for  
894 multiple testing. **E)** Insulin resistance (HOMA-IR) measures did not significantly differ between  
895 the groups, but significantly increased from day 0 to day 28 in both groups. **F)** Glucose  
896 variability, expressed as time between 3.9-10 mmol/L glucose, improved only within the FFT  
897 group between day 0 and day 28, which was nominal significant, but disappeared after  
898 correcting for multiple testing.

899

900 **Figure 2: A)** Overview of the faecal samples used for the bulk metagenomic sequencing (for  
901 bacteriome and phageome) and the metagenomic sequencing of the viral-like particles (VLP).

902 **B)** The richness (number of observed species) in the bacteriome, phage virions (VLP) and  
903 bulk-derived phageome (WGS) from baseline until follow-up at day 28. Though there were no  
904 significant differences between the placebo and faecal filtrate group, the richness in the  
905 bacteriome reduced slightly after both interventions. A similar trend was observed in the  
906 phageome (mostly prophages present in bacterial hosts), while the richness in the VLP fraction  
907 tended to increase slightly at day 2 for both interventions. **C)** The alpha-diversity (Shannon  
908 index) of the bacteriome, phage virions (VLP) and bulk-derived phageome (WGS) from  
909 baseline until follow-up at day 28. Again, no significant differences were found between the  
910 interventions. Similar to the richness, the diversity of the bacteriome and phageome slightly  
911 decreased directly after the interventions. For the free phages, the diversity decreased slightly  
912 in the placebo group, but not in the faecal filtrate group.

913

914 **Figure 3: A)** The percentage of phages that were shared between the donor and recipient  
915 within the phageome and **B)** within the phage virions after the faecal filtrate transplantation.  
916 There was a slight, non-significant increase in the relative abundance of (pro)phages shared  
917 with the donor after the intervention, while the relative abundance of phage virions that were  
918 shared with the donor slightly decreased. **C)** The percentage of new phages that were present  
919 after the intervention within the bulk-derived phageome and **D)** within the phage virions. In  
920 both, the relative abundance of new phages increased over time and although not significant,  
921 this increase was slightly higher in the FFT group.

922

923 **Figure 4: A)** Principal response curve showing how the FFT group differs from the placebo  
924 (set to zero) in the bacteriome, bulk-derived phageome (WGS), and phage virion (VLP)  
925 composition. Significance in dispersion over time and at each separate time-point was  
926 calculated with permutation tests. **B)** Principal component analysis of VLP composition after  
927 centered log-ratio transformation. Large points show the mean of each group. **C)** Log fold  
928 change for all 216 viral populations (VP) indicated as differentially abundant by ANCOM-BC  
929 analysis. For legibility, VP names are not shown, these can be found in supplementary table  
930 S4. **D)** Bacterial host species of which the phages are enriched among differentially abundant  
931 VPs. The first column shows the number of differentially abundant VPs, the second the total  
932 number of VPs linked to a given host in the dataset, and stars show the level of significance  
933 after testing for enrichment with a hypergeometric test. **E)** splits up the data on the first column  
934 of D by participant group.

935

936 **Figure 5: A)** Correlations plots showing the change in relative abundance between day 0 and  
937 day 2 of viral populations (VP) versus host bacteria. Each datapoint represents the interactions  
938 between the VPs and metagenome assembled genomes (MAGs) of a particular species within

939 a given sample. Linkages between VPs and MAGs were based on either CRISPR spacer hits  
940 or the presence of the VP as a prophage in the MAG. The Spearman correlation coefficient  
941 showed that phage-bacterium interactions in FFT samples tended toward antagonism, while  
942 those in placebo samples were protagonistic. **B)** Same as A, but showing the change in  
943 relative abundance between day 2 and day 28. The Spearman correlation coefficient showed  
944 that phage-bacterium interactions in placebo samples were protagonistic. **C)** Same as A and  
945 B, but showing the change in relative abundance between day 0 and day 28. There was no  
946 overall correlation between changes in abundance of VPs and host MAGs.

947

948 **Supplementary figure S1: A)** Recruitment and screening of participants with the metabolic  
949 syndrome. **B)** Recruitment and screening of healthy donors for the sterile faecal filtrate. *BMI*  
950 = *Body Mass Index*; *D. fragilis* = *Dientamoeba fragilis*; *ESBL* = *extended spectrum beta-*  
951 *lactamase producer FMT* = *faecal microbiota transplantation*; *H. pylori* = *Helicobacter pylori*;  
952 *ICF* = *informed consent form*; *PPI* = *proton pump inhibitor*; *STEC* = *shigatoxigenic Escherichia*  
953 *coli*.

954

955 **Supplementary figure S2: A)** Principal component analysis (PCA) of the viral populations  
956 (VP) within the phage virions (VLP) and **B)** bulk-derived phageome (WGS) between the  
957 subjects with metabolic syndrome in the faecal filtrate (FFT) and placebo groups and the  
958 healthy subjects who donated their stool at baseline. There were no differences in overall  
959 composition of the (pro)phages between the groups as determined by permutational analysis  
960 of variance (PERMANOVA). **C)** PCA of the VPs showing the difference in overall  
961 composition between the free phages (VLP) and bulk-derived phageome (WGS), which was  
962 statistically significant as determined by PERMANOVA ( $p = 0.001$ ).

963

964 **Supplementary figure S3: A)** Production of the sterile faecal filtrate started the day before  
965 the administration to the MetSyn subjects. First, stool was collected from a healthy, thoroughly  
966 screened donor, which was homogenized with sterile saline. Large particles were then filtered  
967 from the faecal suspension using double sterile gauzes. Most bacteria were pelleted in two  
968 subsequent centrifugation steps, in which the suspension was spun for 1 hour at 10.000 RCF.  
969 The supernatant was then filtered through a sterile 0.2  $\mu\text{m}$  membrane using a tangential flow  
970 filtration device (Vivaflow® 50). The filtrate was stored overnight in a fridge until administration.  
971 **B)** The sterile faecal filtrate was administered to the patient via a nasoduodenal tube. The day  
972 prior to the administration, subjects were asked to clean their bowel using a laxative, which is  
973 a standard pre-treatment for FMT procedures in our hospital. Nasoduodenal tubes were  
974 placed with the help of a Cortrak device, making sure the nasoduodenal tube was correctly  
975 positioned. The faecal filtrate was slowly infused with a 60 ml syringe, on average 300 ml

976 during a 15-20 min period. **C)** We confirmed with a qPCR for the bacterial 16S rRNA gene the  
977 absence of bacteria within the faecal filtrate, showing a 10<sup>5</sup>-fold decrease in bacterial DNA.  
978 We further confirmed the absence of bacteria by culturing the faecal filtrate, observing no  
979 colony-forming units in 100 ml of faecal filtrate (results not shown). **D)** Overview of the used  
980 pipeline for the microbiome shotgun sequencing and the VLP shotgun sequencing. *MAGs =*  
981 *Metagenome-assembled genomes; QC = quality control; VLP = viral-like particle; WGS =*  
982 *whole genome shotgun.*

983

984 **Table 1:** Baseline characteristics of MetSyn subjects and lean donors.

985 Unless otherwise specified, data are reported as mean (SD). Statistical testing between the  
986 placebo and faecal filtrate groups and metabolic syndrome subjects and donors is performed  
987 by independent Mann-Whitney U test for continuous variables and by Chi-square test for  
988 categorical and binary variables. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood  
989 pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-  
990 density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein.

991

992 **Table 2:** Differences in clinical safety markers after intervention.

993 Unless otherwise specified data are reported as mean (SD). Statistical testing for categorical  
994 and binary variables from the adverse events was done by Chi-square tests. Mixed model  
995 analyses were used to assess differences between groups and timepoints, whereafter post  
996 hoc analyses were performed with Bonferroni correction. Stars indicate statistical significant  
997 differences between day 0 and 28 within a treatment group (\* = P<0.05). The p-value shows  
998 the overall effect of treatment on the variable and only when significant, the adjusted p-values  
999 from the post hoc tests are shown. EA = adverse event; AF = alkaline phosphatase; ALAT =  
1000 alanine aminotransferase; ASAT = aspartate aminotransferase; eGFR = estimated glomerular  
1001 filtration rate; GGT = gamma-glutamyltransferase; MCV = mean corpuscular volume.

1002

1003 **Table 3:** Changes in physical and metabolic variables after intervention.

1004 Unless otherwise specified, data are reported as mean (SD). Mixed model analyses were used  
1005 to assess differences between groups and timepoints, whereafter post hoc analyses were  
1006 performed with Bonferroni correction. Stars indicate statistical significant differences between  
1007 day 0 and 28 within a treatment group (\* = p<0.05; \*\* = p<0.005). The p-value shows the  
1008 overall effect of treatment on the variable and when significant, the adjusted p-values from the  
1009 post hoc tests are shown. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood  
1010 pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-  
1011 density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein.

1012

1013 **Supplementary table S1:** Baseline dietary intake of participants.

1014 Data are reported as mean (SD). Statistical testing between the placebo and fecal filtrate  
1015 groups is performed by independent Mann-Whitney U test.

1016

1017 **Supplementary table 2:** Results from the continuous glucose monitoring devices.

1018 Unless otherwise specified data are reported as mean (SD). Mixed model analyses were used  
1019 to assess differences between groups and timepoints, whereafter post hoc analyses were  
1020 performed with Bonferroni correction. Stars indicate statistical significant differences between  
1021 day 0 and 28 within a treatment group (\* =  $p < 0.05$ ). The p-value shows the overall effect of  
1022 treatment on the variable and only when significant, the adjusted p-values from the post hoc  
1023 tests are shown. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood pressure; HOMA-  
1024 IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-density lipoprotein;  
1025 LDL = low-density lipoprotein; CRP = C-reactive protein.

1026

1027 **Supplementary table S3:** Differentially abundant viral populations within the VLP phageome  
1028 on day 2.

1029

1030 **Supplementary table S4:** In- and exclusion criteria for study participants.







1031 Abbreviations: CVA = cerebrovascular accident; HDL = high-density lipoprotein; HIV = human  
1032 immunodeficiency viruses; HOMA-IR = Homeostatic Model Assessment for Insulin  
1033 Resistance; IBD = inflammatory bowel disease; IBS = irritable bowel syndrome; MI =  
1034 myocardial infarction; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.

1035




1036 **Supplementary table S5:** In- and exclusion criteria for faeces donors.

1037 Abbreviations: AF = alkaline phosphatase; ALAT = alanine aminotransferase; ASAT =  
1038 aspartate aminotransferase; CMV = cytomegalovirus; CRE = Carbapenem-resistant  
1039 Enterobacteriaceae; CRP = C-reactive protein; EBV = Epstein–Barr virus; ESBL = extended  
1040 spectrum beta-lactamase; GGT = gamma-glutamyltransferase; GI = gastrointestinal; HAV =  
1041 hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HEV = hepatitis E virus;  
1042 HIV = human immunodeficiency viruses; HTLV = human T-lymphotropic virus; IBD =  
1043 inflammatory bowel disease; IBS = irritable bowel syndrome; MCV = mean corpuscular  
1044 volume; MRSA = methicillin-resistant Staphylococcus aureus; NCEP = National Cholesterol  
1045 Education Program; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; STEC  
1046 = shigatoxigenic Escherichia coli; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes  
1047 mellitus; VRE = vancomycin-resistant Enterococci.


1048

**A****B****C****D****E****F**

**Figure 1: A)** Overview of the study. **B)** Glucose excursions during the oral glucose tolerance test. One person who was randomized to the FFT group had progressed to type 2 diabetes, which was not apparent at the time of screening. **C)** Total area under the curve (AUC) for glucose and **D)** for C-peptide did not significantly differ between the groups. Within both groups there was a small increase in glucose AUC between day 0 and 28, which was nominal significant within the FFT group, although this significance disappeared after correction for multiple testing. **E)** Insulin resistance (HOMA-IR) measures did not significantly differ between the groups, but significantly increased from day 0 to day 28 in both groups. **F)** Glucose variability, expressed as time between 3.9-10 mmol/L glucose, improved only within the FFT group between day 0 and day 28, which was nominal significant, but disappeared after correcting for multiple testing.




**Figure 2: A)** Overview of the faecal samples used for the bulk metagenomic sequencing (for bacteriome and phageome) and the metagenomic sequencing of the viral-like particles (VLP). **B)** The richness (number of observed species) in the bacteriome, phage virions (VLP) and bulk-derived phageome (WGS) from baseline until follow-up at day 28. Though there were no significant differences between the placebo and faecal filtrate group, the richness in the bacteriome reduced slightly after both interventions. A similar trend was observed in the phageome (mostly prophages present in bacterial hosts), while the richness in the VLP fraction tended to increase slightly at day 2 for both interventions. **C)** The alpha-diversity (Shannon index) of the bacteriome, phage virions (VLP) and bulk-derived phageome (WGS) from baseline until follow-up at day 28. Again, no significant differences were found between the interventions. Similar to the richness, the diversity of the bacteriome and phageome slightly decreased directly after the interventions. For the free phages, the diversity decreased slightly in the placebo group, but not in the faecal filtrate group.




**Figure 3:** **A**) The percentage of phages that were shared between the donor and recipient within the phageome and **B**) within the phage virions after the faecal filtrate transplantation. There was a slight, non-significant increase in the relative abundance of (pro)phages shared with the donor after the intervention, while the relative abundance of phage virions that were shared with the donor slightly decreased. **C**) The percentage of new phages that were present after the intervention within the bulk-derived phageome and **D**) within the phage virions. In both, the relative abundance of new phages increased over time and although not significant, this increase was slightly higher in the FFT group.





**Figure 4:** **A**) Principal response curve showing how the FFT group differs from the placebo (set to zero) in the bacteriome, bulk-derived phageome (WGS), and phage virion (VLP) composition. Significance in dispersion over time and at each separate time-point was calculated with permutation tests. **B**) Principal component analysis of VLP composition after centered log-ratio transformation. Large points show the mean of each group. **C**) Log fold change for all 216 viral populations (VP) indicated as differentially abundant by ANCOM-BC analysis. For legibility, VP names are not shown, these can be found in supplementary table S4. **D**) Bacterial host species of which the phages are enriched among differentially abundant VPs. The first column shows the number of differentially abundant VPs, the second the total number of VPs linked to a given host in the dataset, and stars show the level of significance after testing for enrichment with a hypergeometric test. **E**) splits up the data on the first column of D by participant group.



**Figure 5:** **A)** Correlations plots showing the change in relative abundance between day 0 and day 2 of viral populations (VP) versus host bacteria. Each datapoint represents the interactions between the VPs and metagenome assembled genomes (MAGs) of a particular species within a given sample. Linkages between VPs and MAGs were based on either CRISPR spacer hits or the presence of the VP as a prophage in the MAG. The Spearman correlation coefficient showed that phage-bacterium interactions in FFT samples tended toward antagonism, while those in placebo samples were protagonistic. **B)** Same as A, but showing the change in relative abundance between day 2 and day 28. The Spearman correlation coefficient showed that phage-bacterium interactions in placebo samples were protagonistic. **C)** Same as A and B, but showing the change in relative abundance between day 0 and day 28. There was no overall correlation between changes in abundance of VPs and host MAGs.

**Table 1:** baseline characteristics of MetSyn subjects and lean donors.

	Metabolic Syndrome subjects			Combined (N=24)	Donors (N=5)	<i>p</i> -value
	Placebo (N=12)	Fecal Filtrate (N=12)	<i>P</i> -value			
<b>Age</b> (years)	<b>49.3</b> (12.9)	<b>54.8</b> (8.9)	<i>0.20</i>	<b>52.0</b> (11.2)	<b>32.0</b> (7.81)	<b>0.003</b>
<b>Gender</b> (n (%))						
- Male	<b>7</b> (58.3%)	<b>7</b> (58.3%)	<i>&gt;0.99</i>	<b>14</b> (58.3%)	<b>3</b> (60.0%)	<i>&gt;0.99</i>
- Female	<b>5</b> (41.7%)	<b>5</b> (41.7%)		<b>10</b> (41.7%)	<b>2</b> (40.0%)	
<b>#MetSyn criteria</b> (n (%))						
- 1	-	-	<i>0.38</i>	-	<b>3</b> (60.0%)	<b>&lt;0.001</b>
- 2	-	-		-	<b>2</b> (40.0%)	
- 3	<b>4</b> (33.3%)	<b>7</b> (58.3%)		<b>11</b> (45.8%)	-	
- 4	<b>5</b> (41.7%)	<b>4</b> (33.3%)		<b>9</b> (37.5%)	-	
- 5	<b>3</b> (25.0%)	<b>1</b> (8.3%)		<b>4</b> (16.7%)	-	
<b>BMI</b> (kg/m <sup>2</sup> )	<b>36.1</b> (4.2)	<b>35.2</b> (5.7)	<i>0.76</i>	<b>35.7</b> (4.9)	<b>22.2</b> (1.9)	<b>&lt;0.001</b>
<b>WHR</b>	<b>0.98</b> (0.09)	<b>1.00</b> (0.06)	<i>0.49</i>	<b>0.99</b> (0.07)	<b>0.83</b> (0.07)	<b>&lt;0.001</b>
<b>Systolic BP</b> (mmHg)	<b>147</b> (17)	<b>131</b> (17)	<b>0.047</b>	<b>139</b> (18)	<b>124</b> (5)	<b>0.039</b>
<b>Diastolic BP</b> (mmHg)	<b>93</b> (10)	<b>90</b> (11)	<i>0.74</i>	<b>91</b> (11)	<b>76</b> (5)	<b>0.004</b>
<b>Pulse</b> (beats/min)	<b>66</b> (12)	<b>69</b> (11)	<i>0.77</i>	<b>68</b> (11)	<b>60</b> (11)	<i>0.17</i>
<b>Glucose</b> (mmol/L)	<b>5.6</b> (0.5)	<b>5.7</b> (0.5)	<i>0.99</i>	<b>5.7</b> (0.5)	<b>5.0</b> (0.4)	<b>0.007</b>
<b>Insulin</b> (nmol/L)	<b>85</b> (24)	<b>82</b> (28)	<i>0.83</i>	<b>84</b> (26)	<b>38</b> (12)	<b>&lt;0.001</b>
<b>HOMA-IR</b>	<b>2.91</b> (0.76)	<b>2.92</b> (1.02)	<i>&gt;0.99</i>	<b>2.91</b> (0.88)	<b>1.18</b> (0.37)	<b>&lt;0.001</b>
<b>HbA1c</b> (mmol/mol)	<b>36</b> (3.2)	<b>36</b> (4.3)	<i>0.75</i>	<b>36</b> (3.7)	<b>34</b> (2.1)	<i>0.19</i>
<b>Cholesterol</b> (mmol/L)	<b>5.30</b> (1.13)	<b>5.76</b> (1.53)	<i>0.63</i>	<b>5.53</b> (1.34)	<b>4.01</b> (0.45)	<b>0.015</b>
<b>HDL</b> (mmol/L)	<b>1.15</b> (0.22)	<b>1.22</b> (0.23)	<i>0.52</i>	<b>1.19</b> (0.22)	<b>1.52</b> (0.26)	<b>0.010</b>
<b>LDL</b> (mmol/L)	<b>3.43</b> (0.98)	<b>3.71</b> (1.25)	<i>0.89</i>	<b>3.57</b> (1.11)	<b>2.09</b> (0.58)	<b>0.003</b>
<b>Triglycerides</b> (mmol/L)	<b>1.60</b> (0.58)	<b>1.84</b> (0.75)	<i>0.59</i>	<b>1.72</b> (0.67)	<b>0.89</b> (0.29)	<b>0.007</b>
<b>CRP</b> (mg/L)	<b>4.0</b> (5.1)	<b>6.2</b> (7.3)	<i>0.25</i>	<b>5.1</b> (6.2)	<b>1.4</b> (1.0)	<i>0.07</i>

*Unless otherwise specified, data are reported as mean (SD). Statistical testing between the placebo and fecal filtrate groups and metabolic syndrome subjects and donors is performed by independent Mann-Whitney U test for continuous variables and by Chi-square test for categorical and binary variables. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein.*

**Table 2:** Differences in clinical safety markers after intervention

		<b>Placebo (N=12)</b>	<b>Fecal Filtrate (N=12)</b>	<b>p-value</b>
<b># AEs (n (%))</b>	Total	<b>13 (44.8%)</b>	<b>16 (55.2%)</b>	
<b>Relatedness of AEs (n (%))</b>	Likely	<b>0 (0%)</b>	<b>2 (12.5%)</b>	0.21
	Possibly	<b>2 (15.4%)</b>	<b>6 (37.5%)</b>	
	Unlikely	<b>4 (30.8%)</b>	<b>4 (25%)</b>	
	Not	<b>7 (53.9%)</b>	<b>4 (25%)</b>	
<b># Subjects with AE (n (%))</b>	≥1 AE	<b>2 (16.7%)</b>	<b>6 (50%)</b>	0.08
<i>possibly or likely related</i>	No AE	<b>10 (83.3%)</b>	<b>6 (50%)</b>	
<b>Bilirubin (µmol/L)</b>	Day 0	<b>12 (6)</b>	<b>15 (9)</b>	0.39
	Day 28	<b>9 (5)</b>	<b>12 (12)</b>	
<b>AF (U/L)</b>	Day 0	<b>76 (18)</b>	<b>69 (16)</b>	0.17
	Day 28	<b>79 (16)</b>	<b>68 (16)</b>	
<b>GGT (U/L)</b>	Day 0	<b>22 (10)</b>	<b>26 (11)</b>	0.30
	Day 28	<b>22 (12)</b>	<b>26 (9)</b>	
<b>ASAT (U/L)</b>	Day 0	<b>28 (8)</b>	<b>28 (7)</b>	0.70
	Day 28	<b>27 (8)</b>	<b>25 (7)</b>	
<b>ALAT (U/L)</b>	Day 0	<b>29 (11)</b>	<b>29 (10)</b>	0.85
	Day 28	<b>28 (10)</b>	<b>27 (9)</b>	
<b>Creatinine (µmol/L)</b>	Day 0	<b>85 (18)</b>	<b>76 (15)</b>	0.20
	Day 28	<b>82 (13)</b>	<b>75 (15)</b>	
<b>eGFR (ml/min/1.73m<sup>2</sup>)</b>	Day 0	<b>81 (12)</b>	<b>86 (6)</b>	0.32
	Day 28	<b>83 (9)</b>	<b>85 (7)</b>	
<b>Urea (mmol/L)</b>	Day 0	<b>4.3 (0.9)</b>	<b>4.4 (1.1)</b>	0.65
	Day 28	<b>4.8 (0.9)</b>	<b>5.1 (1.3)</b>	
<b>Haemoglobin (mmol/L)</b>	Day 0	<b>8.5 (1.0)</b>	<b>8.8 (0.8)</b>	0.74
	Day 28	<b>8.6 (0.9)</b>	<b>8.6 (0.6)</b>	
<b>Haematocrit (L/L)</b>	Day 0	<b>0.41 (0.04)</b>	<b>0.42 (0.03)</b>	0.84
	Day 28	<b>0.42 (0.04)</b>	<b>0.41 (0.03)</b>	
<b>MCV (fL)</b>	Day 0	<b>86.0 (4.7)</b>	<b>88.0 (2.7)</b>	0.25
	Day 28	<b>86.5 (4.5)</b>	<b>88.1 (3.0)</b>	
<b>Thrombocytes (x10<sup>9</sup>/L)</b>	Day 0	<b>265 (87)</b>	<b>259 (45)</b>	0.85
	Day 28	<b>263 (73)</b>	<b>259 (48)</b>	
<b>Leukocytes (x10<sup>9</sup>/L)</b>	Day 0	<b>6.2 (1.4)</b>	<b>6.2 (1.2)</b>	0.56
	Day 28	<b>5.8 (1.2)</b>	<b>6.3 (1.4)</b>	
<b>Eosinophils (x10<sup>9</sup>/L)</b>	Day 0	<b>0.15 (0.07)</b>	<b>0.12 (0.06)</b>	0.61
	Day 28	<b>0.16 (0.08)</b>	<b>0.16 (0.11)</b>	


<b>Basophils</b> (x10 <sup>9</sup> /L)	Day 0	<b>0.04</b> (0.01)	<b>0.03</b> (0.02)	0.27
	Day 28	<b>0.04</b> (0.02)	<b>0.04</b> (0.02)	
<b>Neutrophils</b> (x10 <sup>9</sup> /L)	Day 0	<b>3.64</b> (1.14)	<b>3.83</b> (0.97)	0.36
	Day 28	<b>3.25</b> (0.99)	<b>3.82</b> (1.13)	
<b>Lymphocytes</b> (x10 <sup>9</sup> /L)	Day 0	<b>1.83</b> (0.40)	<b>1.70</b> (0.42)	0.61
	Day 28	<b>1.81</b> (0.29)	<b>1.77</b> (0.48)	
<b>Monocytes</b> (x10 <sup>9</sup> /L)	Day 0	<b>0.48</b> (0.11)	<b>0.50</b> (0.10)	0.60
	Day 28	<b>0.47</b> (0.14)	<b>0.50</b> (0.08)	
<b>Immunoglobulins</b> (x10 <sup>9</sup> /L)	Day 0	<b>0.02</b> (0.01)	<b>0.02</b> (0.01)	0.31
	Day 28	<b>0.02</b> (0.01)	<b>0.02</b> (0.01)	

*Unless otherwise specified data are reported as mean (SD). Statistical testing for categorical and binary variables from the adverse events was done by Chi-square tests. Mixed model analyses were used to assess differences between groups and timepoints, whereafter post hoc analyses were performed with Bonferroni correction. Stars indicate statistical significant differences between day 0 and 28 within a treatment group (\* = P<0.05). The p-value shows the overall effect of treatment on the variable and only when significant, the adjusted p-values from the post hoc tests are shown. EA = adverse event; AF = alkaline phosphatase; ALAT = alanine aminotransferase; ASAT = aspartate aminotransferase; eGFR = estimated glomerular filtration rate; GGT = gamma-glutamyltransferase; MCV = mean corpuscular volume.*

**Table 3:** Changes in physical and metabolic variables after intervention.


		<b>Placebo</b> (N=12)	<b>Fecal Filtrate</b> (N=12)	<b>p-value</b>
<b>BMI</b> (kg/m <sup>2</sup> )	Day 0	<b>35.8</b> (4.0)	<b>35.3</b> (5.6)	0.75
	Day 28	<b>36.1</b> (3.9)	<b>35.3</b> (5.8)	
<b>WHR</b>	Day 0	<b>0.97</b> (0.09)	<b>0.99</b> (0.07)	0.58
	Day 28	<b>0.97</b> (0.09)	<b>0.99</b> (0.08)	
<b>Systolic BP</b> (mmHg)	Day 0	<b>134</b> (15)	<b>130</b> (17)	0.39
	Day 28	<b>134</b> (16)	<b>126</b> (17)	
<b>Diastolic BP</b> (mmHg)	Day 0	<b>88</b> (11)	<b>83</b> (14)	0.37
	Day 28	<b>86</b> (9)	<b>84</b> (14)	
<b>Pulse</b> (beats/min)	Day 0	<b>66</b> (9)	<b>70</b> (13)	0.33
	Day 28	<b>65</b> (10)	<b>70</b> (11)	
<b>Glucose</b> (mmol/L)	Day 0	<b>5.5</b> (0.4)	<b>5.8</b> (0.5)	0.19
	Day 28	<b>5.7</b> (0.5)	<b>5.9</b> (0.5)	
<b>Insulin</b> (nmol/L)	Day 0	<b>71</b> (34) *	<b>72</b> (26) **	0.76
	Day 28	<b>87</b> (30)	<b>93</b> (34)	
<b>HOMA-IR</b>	Day 0	<b>2.41</b> (1.21) *	<b>2.57</b> (0.97) **	0.55
	Day 28	<b>3.05</b> (1.06)	<b>3.41</b> (1.28)	
<b>HbA1c</b> (mmol/mol)	Day 0	<b>36.8</b> (2.6)	<b>35.4</b> (4.7)	0.53
	Day 28	<b>35.5</b> (2.5)	<b>35.0</b> (4.5)	
<b>Cholesterol</b> (mmol/L)	Day 0	<b>4.87</b> (0.79)	<b>5.38</b> (1.32)	0.28
	Day 28	<b>4.92</b> (0.78)	<b>5.33</b> (1.15)	
<b>HDL</b> (mmol/L)	Day 0	<b>1.05</b> (0.20) **	<b>1.14</b> (0.18)	0.41
	Day 28	<b>1.15</b> (0.30)	<b>1.21</b> (0.17)	
<b>LDL</b> (mmol/L)	Day 0	<b>3.06</b> (0.77)	<b>3.43</b> (1.08)	0.32
	Day 28	<b>3.03</b> (0.88)	<b>3.42</b> (0.99)	
<b>Triglycerides</b> (mmol/L)	Day 0	<b>1.68</b> (0.61)	<b>1.80</b> (0.61)	0.96
	Day 28	<b>1.66</b> (0.88)	<b>1.56</b> (0.64)	
<b>CRP</b> (mg/L)	Day 0	<b>3.0</b> (2.6)	<b>5.1</b> (4.6)	0.17
	Day 28	<b>2.9</b> (2.9)	<b>4.6</b> (3.4)	

Unless otherwise specified, data are reported as mean (SD). Mixed model analyses were used to assess differences between groups and timepoints, whereafter post hoc analyses were performed with Bonferroni correction. Stars indicate statistical significant differences between day 0 and 28 within a treatment group (\* =  $p < 0.05$ ; \*\* =  $p < 0.005$ ). The p-value shows the overall effect of treatment on the variable and when significant, the adjusted p-values from the post hoc tests are shown. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein.




**Supplementary figure S1: A) Recruitment and screening of participants with the metabolic syndrome. B) Recruitment and screening of healthy donors for the sterile faecal filtrate. BMI = Body Mass Index; D. fragilis = *Dientamoeba fragilis*; ESBL = extended spectrum beta-lactamase producer FMT = faecal microbiota transplantation; H. pylori = *Helicobacter pylori*; ICF = informed consent form; PPI = proton pump inhibitor; STEC = shigatoxigenic *Escherichia coli*.**





**Supplementary figure S2: A)** Principal component analysis (PCA) of the viral populations (VP) within the phage virions (VLP) and **B)** bulk-derived phageome (WGS) between the subjects with metabolic syndrome in the faecal filtrate (FFT) and placebo groups and the healthy subjects who donated their stool at baseline. There were no differences in overall composition of the (pro)phages between the groups as determined by permutational analysis of variance (PERMANOVA). **C)** PCA of the VPs showing the difference in overall composition between the free phages (VLP) and bulk-derived phageome (WGS), which was statistically significant as determined by PERMANOVA ( $p = 0.001$ ).



**Supplementary figure S3: A)** Production of the sterile faecal filtrate started the day before the administration to the MetSyn subjects. First, stool was collected from a healthy, thoroughly screened donor, which was homogenized with sterile saline. Large particles were then filtered from the faecal suspension using double sterile gauzes. Most bacteria were pelleted in two subsequent centrifugation steps, in which the suspension was spun for 1 hour at 10.000 RCF. The supernatant was then filtered through a sterile 0.2 µm membrane using a tangential flow filtration device (Vivaflow® 50). The filtrate was stored overnight in a fridge until administration. **B)** The sterile faecal filtrate was administered to the patient via a nasoduodenal tube. The day prior to the administration, subjects were asked to clean their bowel using a laxative, which is a standard pre-treatment for FMT procedures in our hospital. Nasoduodenal tubes were placed with the help of a Cortrak device, making sure the nasoduodenal tube was correctly positioned. The faecal filtrate was slowly infused with a 60 ml syringe, on average 300 ml during a 15-20 min period. **C)** We confirmed with a qPCR for the bacterial 16S rRNA gene the absence of bacteria within the faecal filtrate, showing a 10<sup>5</sup>-fold decrease in bacterial DNA. We further confirmed the absence of bacteria by culturing the faecal filtrate, observing no colony-forming units in 100 ml of faecal filtrate (results not shown). **D)** Overview of the used pipeline for the microbiome shotgun sequencing and the VLP shotgun sequencing. *MAGs* = Metagenome-assembled genomes; *QC* = quality control; *VLP* = viral-like particle; *WGS* = whole genome shotgun.

**Table S1:** baseline dietary intake of participants.

	<b>Placebo</b> (N=12)	<b>Fecal Filtrate</b> (N=12)	<b>P-value</b>
<b>Energy</b> (kcal)	<b>2199</b> (271)	<b>2146</b> (580)	0.44
<b>Fats</b> (g)	<b>93.4</b> (18.9)	<b>93.3</b> (29.7)	>0.99
<b>Saturated fats</b> (g)	<b>33.8</b> (9.5)	<b>33.0</b> (11.8)	>0.99
<b>Carbohydrates</b> (g)	<b>218.3</b> (51.8)	<b>218.4</b> (70.3)	0.98
<b>Sugars</b> (g)	<b>82.6</b> (30.4)	<b>91.2</b> (44.5)	0.71
<b>Proteins</b> (g)	<b>106.0</b> (26.4)	<b>89.8</b> (25.0)	0.16
<b>Fibers</b> (g)	<b>22.1</b> (6.7)	<b>18.7</b> (6.0)	0.10
<b>Salt</b> (g)	<b>7.72</b> (2.93)	<b>7.50</b> (2.86)	0.89

*Data are reported as mean (SD). Statistical testing between the placebo and fecal filtrate groups is performed by independent Mann-Whitney U test.*

**Table S2:** Results from the continuous glucose monitoring devices measured one week before and one week after intervention.

		<b>Placebo</b> (N=12)	<b>Fecal Filtrate</b> (N=12)	<b>P-value</b>
<b>Mean glucose</b> (mmol/L)	Before	<b>5.36</b> (0.41)	<b>5.37</b> (0.70)	0.75
	After	<b>5.34</b> (0.38)	<b>5.33</b> (0.59)	
<b>SD glucose</b> (mmol/L)	Before	<b>0.89</b> (0.19)	<b>0.98</b> (0.42)	0.58
	After	<b>0.94</b> (0.26)	<b>0.94</b> (0.37)	
<b>CV glucose</b> (%)	Before	<b>16.7</b> (3.6)	<b>17.8</b> (5.1)	0.39
	After	<b>17.5</b> (4.7)	<b>17.3</b> (4.8)	
<b>Min glucose</b> (mmol/L)	Before	<b>3.55</b> (0.47)	<b>3.43</b> (0.37)	0.37
	After	<b>3.51</b> (0.55)	<b>3.46</b> (0.48)	
<b>Max glucose</b> (mmol/L)	Before	<b>8.63</b> (1.21)	<b>8.92</b> (1.74)	0.33
	After	<b>9.18</b> (1.44)	<b>8.82</b> (1.75)	
<b>Time between 3.9-10</b> (%)	Before	<b>97.1</b> (4.5)	<b>95.5</b> (5.4)	0.19
	After	<b>97.3</b> (4.4)	<b>97.5</b> (3.3)	
<b>Est. HbA1c</b> (mmol/mol)	Before	<b>31.0</b> (2.8)	<b>31.1</b> (4.8)	0.76
	After	<b>31.0</b> (2.6)	<b>30.9</b> (4.1)	
<b>AUC/day</b>	Before	<b>7621</b> (991)	<b>7617</b> (823)	0.55
	After	<b>7795</b> (671)	<b>7841</b> (919)	
<b>AUC&gt;2SD/day</b>	Before	<b>33.0</b> (23.5)	<b>32.3</b> (9.5)	0.53
	After	<b>41.4</b> (15.5)	<b>40.6</b> (13.9)	
<b>CONGA 1</b> score	Before	<b>0.99</b> (0.22)	<b>1.09</b> (0.42)	0.28
	After	<b>0.99</b> (0.25)	<b>1.08</b> (0.46)	
<b>MODD</b> score	Before	<b>0.82</b> (0.17)	<b>0.87</b> (0.30)	0.41
	After	<b>0.83</b> (0.20)	<b>0.92</b> (0.39)	
<b>MAGE</b> score	Before	<b>1.68</b> (0.87)	<b>1.81</b> (1.03)	0.32
	After	<b>1.45</b> (0.47)	<b>1.53</b> (0.72)	

Unless otherwise specified data are reported as mean (SD). Mixed model analyses were used to assess differences between groups and timepoints, whereafter post hoc analyses were performed with Bonferroni correction. Stars indicate statistical significant differences between the week before and after intervention within a treatment group (\* =  $P < 0.05$ ). The P-value shows the overall effect of treatment on the variable and only when significant, the adjusted P-values from the post hoc tests are shown. BMI = Body Mass Index; WHR = waist-hip ratio; BP = blood pressure; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HDL = high-density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein.

**Table S3:** Differentially abundant viral populations within the VLP phageome on day 2.

VP	pval	qval	logFoldChange	se	group
k141_101636	0	0	-1,312270403	0	FFT
k141_102263	0	0	-3,425670312	0	FFT
k141_106332	0	0	2,141087406	0	Placebo
k141_10756	3,15E-05	0,017617	5,563830378	1,336678	Placebo
k141_10974	0	0	2,992127571	0	Placebo
k141_109788	0	0	-1,375429495	0	FFT
k141_11046	0	0	-0,962092831	0	FFT
k141_111221	0	0	-1,453290059	0	FFT
k141_112035	0	0	-3,3466534	0	FFT
k141_112086	0	0	3,104251722	0	Placebo
k141_112454	0	0	2,827791675	0	Placebo
k141_114032	0	0	3,294213547	0	Placebo
k141_115416	0	0	-3,333017439	0	FFT
k141_11637	0	0	-1,401340226	0	FFT
k141_116603	0	0	-1,086477395	0	FFT
k141_11730	0	0	2,503402317	0	Placebo
k141_117761	0	0	2,60659704	0	Placebo
k141_119045	0	0	3,564093484	0	Placebo
k141_125759	0	0	2,952167989	0	Placebo
k141_125789	0	0	-2,067780338	0	FFT
k141_127001	0	0	2,749757395	0	Placebo
k141_127793	0	0	3,893689588	0	Placebo
k141_128877	0	0	2,126697451	0	Placebo
k141_129314	0	0	-3,025927151	0	FFT
k141_134605	0	0	-3,292277297	0	FFT
k141_136941	0	0	-1,277341305	0	FFT
k141_144884	0	0	-1,056548645	0	FFT
k141_148750	0	0	-2,604840048	0	FFT

VP	pval	qval	logFoldChange	se	group
k141_151057	0	0	-2,126112954	0	FFT
k141_15115	0	0	-1,817210155	0	FFT
k141_151150_1	0	0	-1,438756269	0	FFT
k141_155147	0	0	-2,05749536	0	FFT
k141_155148	0	0	-2,000236329	0	FFT
k141_157965	0	0	3,605717171	0	Placebo
k141_158364_dd0	0	0	2,187755549	0	Placebo
k141_159779	0	0	2,239116789	0	Placebo
k141_159817	0	0	2,120457402	0	Placebo
k141_161268	0	0	2,586662105	0	Placebo
k141_16485	0	0	-0,9932292	0	FFT
k141_168380	0	0	-0,855276508	0	FFT
k141_170194	0	0	-1,719024655	0	FFT
k141_172768	0	0	2,601083591	0	Placebo
k141_177455	0	0	-1,6607376	0	FFT
k141_178132	0	0	-3,741877558	0	FFT
k141_179489	0	0	-1,950095228	0	FFT
k141_180382	0	0	-2,089345501	0	FFT
k141_180582	0	0	-2,640651363	0	FFT
k141_183972	0	0	1,804298089	0	Placebo
k141_187104	0	0	-2,543229341	0	FFT
k141_190599	0	0	2,052310446	0	Placebo
k141_193501	0	0	-1,592000751	0	FFT
k141_194688	0	0	-2,76451363	0	FFT
k141_198836	0	0	2,803009107	0	Placebo
k141_199825	0	0	2,928490685	0	Placebo
k141_200995	0	0	-3,144102303	0	FFT
k141_202610	0	0	-1,770629428	0	FFT
k141_203084	0	0	-2,053202875	0	FFT
k141_203139	0	0	-1,891220481	0	FFT

VP	pval	qval	logFoldChange	se	group
k141_206365	0	0	-1,129053941	0	FFT
k141_20647	0	0	2,789096554	0	Placebo
k141_206857	0	0	-2,412442161	0	FFT
k141_206980	0	0	-3,31697338	0	FFT
k141_209161	0	0	-1,438294024	0	FFT
k141_210395	0	0	-0,724058392	0	FFT
k141_212095	0	0	-2,712640916	0	FFT
k141_21677	0	0	-2,358183947	0	FFT
k141_21921	0	0	2,540045123	0	Placebo
k141_22024_dd0	0	0	2,51659235	0	Placebo
k141_22092	0	0	2,069173303	0	Placebo
k141_22286	0	0	-2,327372111	0	FFT
k141_233879	0	0	-3,125257489	0	FFT
k141_234523	0	0	-1,801032357	0	FFT
k141_24053	0	0	-2,524172434	0	FFT
k141_242230	0	0	-2,326845426	0	FFT
k141_251286	0	0	-2,990744268	0	FFT
k141_254742	0	0	-3,43670237	0	FFT
k141_26090	0	0	-1,358243264	0	FFT
k141_261577	0	0	-3,163270958	0	FFT
k141_261638	0	0	-1,647922065	0	FFT
k141_26711	0	0	-3,241422347	0	FFT
k141_29930	0	0	-2,376517194	0	FFT
k141_31428	0	0	1,973812533	0	Placebo
k141_31803	0	0	-1,671578554	0	FFT
k141_33432	0	0	-2,056664518	0	FFT
k141_35243	0	0	-3,760521856	0	FFT
k141_35795_dd0	0	0	3,691541787	0	Placebo
k141_3625_dd0	0	0	-1,698719279	0	FFT
k141_37010	0	0	-1,069830093	0	FFT

VP	pval	qval	logFoldChange	se	group
k141_39074	0	0	-1,222252937	0	FFT
k141_3911	0	0	-2,633100111	0	FFT
k141_4122_dd0	0	0	-2,987212781	0	FFT
k141_41301	0	0	-1,885353218	0	FFT
k141_4169	0	0	-2,393193791	0	FFT
k141_4369	0	0	-1,935620837	0	FFT
k141_44711	0	0	-3,161460603	0	FFT
k141_44931	0	0	-2,0575856	0	FFT
k141_46528	0	0	-1,495563103	0	FFT
k141_46916	0	0	2,093268463	0	Placebo
k141_50348	0	0	3,107055989	0	Placebo
k141_5205	0	0	2,72654519	0	Placebo
k141_53075	0	0	-1,489601858	0	FFT
k141_55453	0	0	-3,434321805	0	FFT
k141_55621	0	0	-1,300409181	0	FFT
k141_56634	0	0	4,455598366	0	Placebo
k141_59760	0	0	1,789431267	0	Placebo
k141_60050	0	0	-0,956952804	0	FFT
k141_61833	0	0	-1,567715024	0	FFT
k141_63935	0	0	-1,327620271	0	FFT
k141_67734	0	0	-4,292240944	0	FFT
k141_69194	0	0	-2,556814394	0	FFT
k141_74094	0	0	3,109323778	0	Placebo
k141_74505	3,96E-05	0,017617	-7,711976292	1,876533	FFT
k141_79107	0	0	2,828070797	0	Placebo
k141_80279	0	0	-2,065397124	0	FFT
k141_81009	0	0	-1,448638782	0	FFT
k141_82007	0	0	-3,740279483	0	FFT
k141_82108	0	0	-1,809720032	0	FFT



VP	pval	qval	logFoldChange	se	group
k141_82112	0	0	4,004910143	0	Placebo
k141_82230	0	0	-1,579494971	0	FFT
k141_82338	0	0	4,826652241	0	Placebo
k141_83004	0	0	-3,415628397	0	FFT
k141_83924_1	0	0	-2,644498789	0	FFT
k141_85097	0	0	2,446543432	0	Placebo
k141_86169	0	0	-2,183651358	0	FFT
k141_86881	0	0	-2,862591441	0	FFT
k141_88495	0	0	-1,906655653	0	FFT
k141_90585	0	0	-2,187977143	0	FFT
k141_91439	0	0	-2,668648043	0	FFT
k141_9187	0	0	-1,848616845	0	FFT
k141_92904	0	0	-2,144436067	0	FFT
k141_9625	0	0	-1,452380852	0	FFT
k141_96613	2,51E-05	0,017617	6,630253453	1,573398	Placebo
NODE_1050_length_55972_cov_117.387789	0	0	2,531114889	0	Placebo
NODE_1088_length_50062_cov_24.574080	0	0	-2,93117887	0	FFT
NODE_11335_length_8998_cov_10.494689_1	0	0	-0,601774626	0	FFT
NODE_1134_length_59393_cov_104.580977	0	0	2,37934413	0	Placebo
NODE_117_length_159210_cov_262.254262	0	0	2,031024034	0	Placebo
NODE_11810_length_12626_cov_114.894042	0	0	2,069339833	0	Placebo
NODE_12_length_255453_cov_103.251267	0	0	-1,747789933	0	FFT
NODE_126_length_166884_cov_17.994923_1	0	0	2,08420609	0	Placebo
NODE_1295_length_46075_cov_193.830769	0	0	-1,843780627	0	FFT
NODE_1308_length_46212_cov_78.801937	0	0	-0,776757044	0	FFT
NODE_14389_length_7854_cov_4.950635	0	0	-0,872967795	0	FFT
NODE_1521_length_45571_cov_101.768455_1	0	0	-1,22638905	0	FFT

VP	pval	qval	logFoldChange	se	group
NODE_16_length_348042_cov_111.631501	0	0	-2,419872421	0	FFT
NODE_1611_length_46733_cov_17.599276_1	0	0	-0,959774804	0	FFT
NODE_16481_length_6520_cov_3.993039	0	0	1,838474041	0	Placebo
NODE_1723_length_41816_cov_164.001125	0	0	2,358019402	0	Placebo
NODE_173_length_134896_cov_7.537018	0	0	-1,286404349	0	FFT
NODE_181_length_130009_cov_37.555966	0	0	3,181861878	0	Placebo
NODE_1820_length_49117_cov_63.722739	0	0	-1,471679648	0	FFT
NODE_1855_length_40494_cov_32.093326	0	0	-1,429529654	0	FFT
NODE_19219_length_6100_cov_6.030108	0	0	-1,02553031	0	FFT
NODE_1966_length_28637_cov_22.336540	0	0	2,031166381	0	Placebo
NODE_19722_length_5869_cov_356.798934_1	0	0	-0,984707094	0	FFT
NODE_2038_length_45256_cov_74.924847	0	0	-1,515460846	0	FFT
NODE_2060_length_37621_cov_353.873929	0	0	3,213898211	0	Placebo
NODE_20787_length_5324_cov_191.477130	0	0	-1,061439074	0	FFT
NODE_21872_length_5396_cov_6.531361	0	0	-0,764365111	0	FFT
NODE_22_length_277594_cov_157.660469	0	0	2,416492446	0	Placebo
NODE_2266_length_36032_cov_331.272146	0	0	2,230878198	0	Placebo
NODE_2327_length_41251_cov_43.961088	0	0	-2,969473485	0	FFT
NODE_248_length_103337_cov_52.835799	0	0	-1,493380762	0	FFT
NODE_256_length_119475_cov_53.713440	0	0	-1,51687262	0	FFT
NODE_2719_length_30411_cov_12.217321	0	0	-1,271940551	0	FFT
NODE_2721_length_29602_cov_28.053948	0	0	-1,238190863	0	FFT
NODE_274_length_129349_cov_49.597383	0	0	-1,784760686	0	FFT
NODE_280_length_83712_cov_192.013531_1	0	0	-0,970377102	0	FFT
NODE_303_length_102870_cov_97.940048	0	0	-1,341981246	0	FFT
NODE_311_length_101570_cov_39.049008	0	0	-1,467845887	0	FFT
NODE_3347_length_27440_cov_41.328611	0	0	2,852704375	0	Placebo
NODE_3362_length_31037_cov_71.806791	0	0	-1,727094403	0	FFT

VP	pval	qval	logFoldChange	se	group
NODE_3432_length_26142_cov_7.044045	0	0	-1,472020258	0	FFT
NODE_3515_length_22106_cov_30.525056	0	0	-1,364903091	0	FFT
NODE_3517_length_22201_cov_1016.884268	0	0	2,107768855	0	Placebo
NODE_352_length_98964_cov_58.192854	0	0	-1,14321944	0	FFT
NODE_3646_length_21525_cov_5.247322	0	0	-0,984906952	0	FFT
NODE_3879_length_25805_cov_66.517631	0	0	2,214577766	0	Placebo
NODE_429_length_105199_cov_116.740565	0	0	-2,314109721	0	FFT
NODE_4406_length_18765_cov_17.720898	0	0	2,703695862	0	Placebo
NODE_448_length_82328_cov_242.488848	0	0	-1,662422888	0	FFT
NODE_4564_length_24187_cov_17.473852	0	0	-0,722987639	0	FFT
NODE_4601_length_26378_cov_20.827565	0	0	-1,502111658	0	FFT
NODE_4627_length_18353_cov_21.879167	0	0	-1,286468209	0	FFT
NODE_467_length_77994_cov_91.581044	0	0	-3,186160602	0	FFT
NODE_47_length_245394_cov_57.668312	0	0	-2,640133738	0	FFT
NODE_4813_length_20685_cov_8.087009	0	0	-1,581883112	0	FFT
NODE_484_length_65443_cov_20.397810	0	0	-1,471379026	0	FFT
NODE_50_length_209392_cov_41.016590	0	0	-1,90625978	0	FFT
NODE_50_length_233022_cov_28.249211_1	0	0	-1,529824626	0	FFT
NODE_508_length_81568_cov_59.029860	0	0	-1,914695115	0	FFT
NODE_5219_length_19530_cov_658.240770	0	0	2,633221576	0	Placebo
NODE_54_length_230968_cov_83.819361	0	0	-2,814716438	0	FFT
NODE_553_length_96146_cov_103.323038	0	0	-1,664989219	0	FFT
NODE_557_length_72009_cov_41.425842	0	0	2,774501699	0	Placebo
NODE_5611_length_15188_cov_13.744069	0	0	-1,115581586	0	FFT
NODE_5616_length_15178_cov_8.516234	0	0	-1,895818223	0	FFT
NODE_564_length_77280_cov_7.587258	0	0	2,502440408	0	Placebo
NODE_60_length_202357_cov_80.827332	0	0	2,377545927	0	Placebo
NODE_607_length_71456_cov_27.699164	0	0	-1,449995967	0	FFT
NODE_617_length_77023_cov_22.896113	0	0	-2,524199258	0	FFT

<b>VP</b>	<b>pval</b>	<b>qval</b>	<b>logFoldChange</b>	<b>se</b>	<b>group</b>
NODE_6423_length_14205_cov_50.890742	0	0	2,068337809	0	Placebo
NODE_69_length_193138_cov_81.982287_1	0	0	-0,910501471	0	FFT
NODE_703_length_67960_cov_56.511420	0	0	-2,240779078	0	FFT
NODE_707_length_80900_cov_37.907774_1	0	0	2,650128324	0	Placebo
NODE_750_length_74789_cov_31.001913	0	0	3,218506179	0	Placebo
NODE_7814_length_12923_cov_5.996114	0	0	-1,126018207	0	FFT
NODE_795_length_63964_cov_11.828146	0	0	-1,795548672	0	FFT
NODE_814_length_67071_cov_27.754984	0	0	-2,214361803	0	FFT
NODE_8630_length_10350_cov_19.728120	0	0	2,893361393	0	Placebo
NODE_864_length_75884_cov_56.634441	0	0	-1,630389453	0	FFT
NODE_869_length_61737_cov_16.350880	0	0	3,034395765	0	Placebo
NODE_871_length_69794_cov_33.084601	0	0	-1,352282376	0	FFT
NODE_904_length_60482_cov_105.096497	0	0	-1,470887833	0	FFT
NODE_944_length_45651_cov_224.138302	0	0	-1,210253855	0	FFT
NODE_9981_length_7650_cov_12.550757_1	0	0	-1,017230505	0	FFT

**Table S4:** In- and exclusion criteria for study participants.

---

<b>INCLUSION CRITERIA</b>
<ul style="list-style-type: none"><li>- Caucasian male or female</li><li>- Age: 18 - 65 years old</li><li>- BMI <math>\geq</math> 25 kg/m<sup>2</sup></li><li>- At least 3 of the following criteria:<ul style="list-style-type: none"><li>o Fasting plasma glucose <math>\geq</math> 5.6 mmol/L, or HOMA-IR index <math>\geq</math> 2.5 (HOMA-IR is measured as (fasting insulin (pmol/L) x fasting glucose (mmol/L)) / 135)</li><li>o Waist-circumference <math>\geq</math> 102 cm for males, <math>\geq</math> 89 cm for females</li><li>o HDL-cholesterol <math>\leq</math> 1.02 mmol/L for males, <math>\leq</math> 1.29 mmol/L for females</li><li>o Blood pressure <math>\geq</math> 130/85 mmHg</li><li>o Triglycerides <math>\geq</math> 1.7 mmol/L</li></ul></li><li>- Subjects should be able to give informed consent</li></ul>
<b>EXCLUSION CRITERIA</b>
<ul style="list-style-type: none"><li>- A history of cardiovascular event (e.g., CVA or MI) or pacemaker implantation</li><li>- Use of any medication including proton pump inhibitors, antibiotics, and pro-/prebiotics in the past three months or during the study period</li><li>- (Expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count <math>&lt;</math> 240/mm<sup>3</sup>)</li><li>- Presence of overt T1DM or T2D</li><li>- History of chronic diarrhoea (<math>\geq</math> 3 stools/day for <math>&gt;</math> 4 weeks), chronic obstipation (<math>&lt;</math> 2 defecations/week for <math>&gt;</math> 3 months), IBS (according to Rome IV criteria), or IBD.</li><li>- Smoking or illicit drug use in the past three months or use during the study period</li><li>- Alcohol abuse (<math>&gt;</math> 5 units/day on average) in the past three months or use of <math>&gt;</math> 2 units/day of alcohol during the study period</li><li>- History of cholecystectomy</li></ul>

---

*Abbreviations: CVA = cerebrovascular accident; HDL = high-density lipoprotein; HIV = human immunodeficiency viruses; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; IBD = inflammatory bowel disease; IBS = irritable bowel syndrome; MI = myocardial infarction; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.*

**Table S5:** In- and exclusion criteria for faeces donors.

---

<b>INCLUSION CRITERIA</b>
<ul style="list-style-type: none"><li>- Caucasian male or female</li><li>- Age: 18 – 65 years old</li><li>- BMI: 18-25 kg/m<sup>2</sup></li><li>- Subjects should be able to give informed consent</li></ul>

---

<b>EXCLUSION CRITERIA</b>
<b>Positive test for infectious agent</b> <ul style="list-style-type: none"><li>- Positive Dual Faeces Test for <i>Giardia Lamblia</i>, <i>Dientamoeba fragilis</i>, <i>Entamoeba histolytica</i>, <i>Microsporidium</i> spp., <i>Cryptosporidium</i> spp., <i>Cyclospora</i>, <i>Isospora</i>, or <i>Blastocystis Hominis</i>. Positive microscopic exam for eggs, cysts, and larvae (e.g. helminth eggs)</li><li>- Presence of faecal bacterial pathogens <i>Salmonella</i> spp., <i>Shigella</i> spp., <i>Campylobacter</i> spp., <i>Yersinia</i> spp., <i>C. difficile</i>, <i>H. pylori</i>, STEC, <i>Aeromonas</i> spp., or <i>Pleisiomonas shigelloides</i> in faeces</li><li>- Presence of ESBL producers, CRE, VRE, or MRSA in faeces</li><li>- Presence of <i>Rotavirus</i>, <i>Norovirus</i> I/II, <i>Enterovirus</i>, <i>Parechovirus</i>, <i>Astrovirus</i>, <i>Sapovirus</i>, or <i>Adenovirus</i> in faeces</li><li>- Presence of SARS-CoV-2 in faeces</li><li>- Positive serologic test for HIV 1/2, HAV, HBV, HCV, HEV, active CMV or EBV, <i>Strongyloides</i>, or <i>Treponema pallidum</i></li></ul>
<b>Risk of infectious agent</b> <ul style="list-style-type: none"><li>- History of, or known exposure to HIV, HBV, HCV, syphilis, HTLV I and II, malaria, trypanosomiasis, or tuberculosis</li><li>- Known systemic infection not controlled at the time of donation</li><li>- Unsafe sex practice</li><li>- Previous reception of tissue/organ transplant</li><li>- Previous (&lt;12 months) reception of blood products</li><li>- Recent (&lt;6 months) needle stick accident</li><li>- Recent (&lt;6 months) body tattoo, piercing, earring, or acupuncture</li><li>- Recent medical treatment in poorly hygienic conditions</li><li>- Risk of transmission of diseases caused by prions</li><li>- Recent parasitosis or infection from rotavirus, <i>Giardia lamblia</i>, and other microbes with GI involvement</li><li>- Recent travel to tropical countries, countries at high risk of communicable diseases, or traveller's diarrhoea</li><li>- Recent (&lt;6 months) history of vaccination with a live attenuated virus, if there is a possible risk of transmission</li><li>- Healthcare providers having frequent patient contact</li><li>- Individual working with animals</li></ul>

---

---

### **Gastrointestinal comorbidities**

- History of IBS (according to Rome IV criteria), IBD, functional chronic constipation, or other chronic GI disorders
- History of chronic, systemic autoimmune disorders with GI involvement, such as coeliac disease
- History of, or high risk for, GI cancer, or polyposis
- Recent appearance of diarrhoea ( $\geq 3$  stools/day), and/or haematochezia
- Elevated faecal calprotectin ( $> 50 \mu\text{g/g}$ )

### **Factors affecting intestinal microbiota composition**

- Use of any medication including proton pump inhibitors, antibiotics, and pro-/prebiotics in the past three months or during the study period
- Smoking or illicit drug use in the past three months or during the study period
- History of cholecystectomy

### **Other conditions**

- History of neurological or neurodegenerative disorders
- History of psychiatric conditions
- Presence of chronic low-grade inflammation or metabolic syndrome (NCEP criteria)
- Presence of T1DM, T2DM, or hypertension
- Alcohol abuse ( $>5$  units/day on average) in the past three months or use of  $> 2$  units/day of alcohol during the study period
- Abnormal liver or renal function (creatinine  $>110 \mu\text{mol/l}$ , ureum  $>8,2 \text{ mmol/l}$ , ASAT  $> 40 \text{ U/L}$ , ALAT  $> 45 \text{ U/L}$ , AF  $> 120 \text{ U/L}$ , GGT  $> 60 \text{ U/L}$ , bilirubin  $>17\mu\text{mol/L}$ ), or impaired immunity (CRP  $> 5 \text{ mg/L}$ , haemoglobin  $< 8,5 \text{ mmol/L}$ , MCV:  $80\text{-}100 \text{ fL}$ , leukocytes:  $4,0\text{-}10,5 \times 10^9/\text{L}$ , thrombocytes:  $150\text{-}400 \times 10^9/\text{L}$ ).

---

*Abbreviations: AF = alkaline phosphatase; ALAT = alanine aminotransferase; ASAT = aspartate aminotransferase; CMV = cytomegalovirus; CRE = Carbapenem-resistant Enterobacteriaceae; CRP = C-reactive protein; EBV = Epstein–Barr virus; ESBL = extended spectrum beta-lactamase; GGT = gamma-glutamyltransferase; GI = gastrointestinal; HAV = hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HEV = hepatitis E virus; HIV = human immunodeficiency viruses; HTLV = human T-lymphotropic virus; IBD = inflammatory bowel disease; IBS = irritable bowel syndrome; MCV = mean corpuscular volume; MRSA = methicillin-resistant Staphylococcus aureus; NCEP = National Cholesterol Education Program; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; STEC = shigatoxigenic Escherichia coli; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; VRE = vancomycin-resistant Enterococci.*